Simm personal page - To The Moon

Simm

Simm

No personal profile

80Follow

1Followers

0Topic

0Badge

06-10

Share your opinion about this news…

3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)

2022-05-20

Bla bka bla bla...but life must go on, hold steady and continue to have faith

Sorry, the original content has been removed

2021-08-04

Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?

Pfizer hikes 2021 outlook after vaccine boosts sales, profit

2021-08-04

Turn to RED MOON now!

2021-08-04

Toyota! My trusted car

Toyota posts record $9.2 bln quarterly operating profit on sales rebound

2021-08-04

Inari has good prospect! At 18x is a good bargain

3 COVID Stocks That Could Soar Higher

2021-07-28

Anyone drinking beers

2021-07-27

Nice beer, Samual Adam

2021-07-21

???

奈雪的茶跌近4% 较招股价已跌超35%

2021-07-21

What about Nio; Xpeng Lucid etc etc ?

Sorry, the original content has been removed

2021-07-21

What happen to Blue zmoon? Turning to Red Moon now

HK-listed Blue Moon Group hits record low as co forecasts H1 loss

2021-07-20

Chewy! Chewy!

2021-07-09

Worth researching Abbots

2021-07-08

When is the right timing to enter?

2021-07-08

Almost become a cinema giants

2021-06-30

$NAYUKI(02150)$?

2021-06-29

?‍?

2021-06-23

Great ariticle, would you like to share it?

Why U.S. stocks face a tough decade ahead even if corporate revenues are strong

2021-06-21

Will the drop ripple to Lithium and battery stock as well?

EV stocks fell in morning trading

2021-06-20

Great ariticle, would you like to share it?

U.S. IPO Week Ahead: Billion-Dollar Deals Come To Market In A 12 IPO Week

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3574328305423311","uuid":"3574328305423311","gmtCreate":1611235097167,"gmtModify":1620450783533,"name":"Simm","pinyin":"simm","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":80,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":315223422099496,"gmtCreate":1717990269853,"gmtModify":1717990271913,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/315223422099496","repostId":"2441307342","repostType":2,"repost":{"id":"2441307342","pubTimestamp":1717988788,"share":"https://ttm.financial/m/news/2441307342?lang=&edition=fundamental","pubTime":"2024-06-10 11:06","market":"us","language":"en","title":"3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)","url":"https://stock-news.laohu8.com/highlight/detail?id=2441307342","media":"Motley Fool","summary":"Palantir's latest AI product has been a game changer for the company.","content":"<html><head></head><body><ul style=\"\"><li><p>Palantir&#39;s revenue growth accelerated, thanks to AIP.</p></li><li><p>Management steadily guided for its profit margins to increase.</p></li><li><p>However, the stock is expensive for its growth rate.</p></li></ul><p>In the realm of artificial intelligence (AI) software, Palantir Technologies sticks out from the rest. Palantir has been in the AI business since its founding in 2003. Originally created to assist governments in processing data to deliver actionable insights, it has since expanded into the public sector, opening up a new business avenue.</p><p>With Palantir&#39;s multiple decades of expertise, it&#39;s becoming a top pick for companies looking to integrate AI models and decision-making into their businesses. Investors are noticing that momentum, piling into the stock as a result.</p><p>I agree that Palantir is a top AI pick, and I have three reasons why it&#39;s a buy. But I have one reason to avoid the stock, and it may trump the rest.</p><h2 id=\"id_1590136905\">Reason to buy 1: Palantir&#39;s latest product has been a hit</h2><p>While some of Palantir&#39;s AI tools have been around for a while, its latest product, Artificial Intelligence Platform (AIP), has been all the rage. While AIP probably could have used a better name (Palantir&#39;s other products sport cooler names like Foundry, Gotham, and Apollo), it gets the point across for what it does.</p><p>AIP gives clients the tools they need to integrate AI into everyday workflows. By centralizing all data flows into one location, AIP helps businesses make decisions on the most up-to-date information they have. It also allows large language model integration (the technology behind generative AI), which further arms users to automate and streamline workflows.</p><p>Palantir&#39;s management consistently used the word &#34;unprecedented&#34; when discussing AIP demand, and this platform will be a major revenue driver for years to come.</p><h2 id=\"id_3457250373\">Reason to buy 2: Revenue growth is accelerating</h2><p>Due to the &#34;unprecedented&#34; demand, Palantir&#39;s revenue growth has been accelerating. In Q1, revenue grew at a 21% clip to $634 million, the fastest pace since late 2022.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/398901b69af0a0d6cedf1e6549522e0d\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR Revenue (Quarterly YoY Growth) data by YCharts</p><p>But Palantir isn&#39;t stopping there. In Q2, management expects revenue of $651 million, indicating 22% revenue growth. Growth acceleration is something investors love to see, and its quicker growth rates help justify the stock price.</p><p>Still, Palantir isn&#39;t just a growth-at-all-costs company.</p><h2 id=\"id_1319693756\">Reason to buy 3: Palantir&#39;s margins continue to improve</h2><p>Palantir flipped the profitability switch in 2023 when it started producing small profits. Since then, its profit margins have continued to steadily tick up, which can be an incredibly powerful combination when revenue growth is also accelerating.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0a76b561140032c2fb8f417ebc677628\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR Profit Margin (Quarterly) data by YCharts</p><p>Palantir&#39;s management understands that investors want to see profits eventually, so it is aligning business results with shareholder expectations. </p><h2 id=\"id_4137751275\">Reason to avoid: Palantir&#39;s stock is far from cheap</h2><p>Palantir checks all the boxes from a business outlook and financial standpoint, but there&#39;s still one more factor to consider: its price tag.</p><p>Even if everything about a stock is perfect, buying it at the wrong price can be a disaster. For example, <strong><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</strong> was a no-brainer stock during the pandemic. It had unbelievable growth, strong profits, and an incredible outlook, but anyone who bought at elevated levels in late 2020 is down nearly 90% from their initial investment.</p><p>Palantir&#39;s stock hasn&#39;t reached near the hubris as Zoom Video&#39;s did, but it&#39;s still valued at a hefty premium.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3cb97bd6ab11a774071bcb94f5fa4077\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR PS Ratio data by YCharts</p><p>At 21 times sales, its price-to-sales (P/S) ratio is nearly equal to its growth rate. This normally doesn&#39;t bode well for a stock, as it indicates incredibly high growth expectations.</p><p>But is that enough to completely avoid the stock? I don&#39;t think so. If investors avoided companies like <strong>Amazon </strong>or <strong>Nvidia </strong>because they were too expensive, they&#39;d have missed out on massive winners. However, highly priced stocks can be volatile, so you&#39;ll need to set a longer holding period of around five years to make it worth it.</p><p>If you can do that, then Palantir could be a fantastic AI investment at these levels.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-10 11:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir's revenue growth accelerated, thanks to AIP.Management steadily guided for its profit margins to increase.However, the stock is expensive for its growth rate.In the realm of artificial ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc.","BK4548":"巴美列捷福持仓","BK4543":"AI","BK4547":"WSB热门概念","BK4551":"寇图资本持仓","BK4097":"系统软件","BK4505":"高瓴资本持仓","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4528":"SaaS概念","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4023":"应用软件","BK4525":"远程办公概念","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4535":"淡马锡持仓"},"source_url":"https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2441307342","content_text":"Palantir's revenue growth accelerated, thanks to AIP.Management steadily guided for its profit margins to increase.However, the stock is expensive for its growth rate.In the realm of artificial intelligence (AI) software, Palantir Technologies sticks out from the rest. Palantir has been in the AI business since its founding in 2003. Originally created to assist governments in processing data to deliver actionable insights, it has since expanded into the public sector, opening up a new business avenue.With Palantir's multiple decades of expertise, it's becoming a top pick for companies looking to integrate AI models and decision-making into their businesses. Investors are noticing that momentum, piling into the stock as a result.I agree that Palantir is a top AI pick, and I have three reasons why it's a buy. But I have one reason to avoid the stock, and it may trump the rest.Reason to buy 1: Palantir's latest product has been a hitWhile some of Palantir's AI tools have been around for a while, its latest product, Artificial Intelligence Platform (AIP), has been all the rage. While AIP probably could have used a better name (Palantir's other products sport cooler names like Foundry, Gotham, and Apollo), it gets the point across for what it does.AIP gives clients the tools they need to integrate AI into everyday workflows. By centralizing all data flows into one location, AIP helps businesses make decisions on the most up-to-date information they have. It also allows large language model integration (the technology behind generative AI), which further arms users to automate and streamline workflows.Palantir's management consistently used the word \"unprecedented\" when discussing AIP demand, and this platform will be a major revenue driver for years to come.Reason to buy 2: Revenue growth is acceleratingDue to the \"unprecedented\" demand, Palantir's revenue growth has been accelerating. In Q1, revenue grew at a 21% clip to $634 million, the fastest pace since late 2022.PLTR Revenue (Quarterly YoY Growth) data by YChartsBut Palantir isn't stopping there. In Q2, management expects revenue of $651 million, indicating 22% revenue growth. Growth acceleration is something investors love to see, and its quicker growth rates help justify the stock price.Still, Palantir isn't just a growth-at-all-costs company.Reason to buy 3: Palantir's margins continue to improvePalantir flipped the profitability switch in 2023 when it started producing small profits. Since then, its profit margins have continued to steadily tick up, which can be an incredibly powerful combination when revenue growth is also accelerating.PLTR Profit Margin (Quarterly) data by YChartsPalantir's management understands that investors want to see profits eventually, so it is aligning business results with shareholder expectations. Reason to avoid: Palantir's stock is far from cheapPalantir checks all the boxes from a business outlook and financial standpoint, but there's still one more factor to consider: its price tag.Even if everything about a stock is perfect, buying it at the wrong price can be a disaster. For example, Zoom Video Communications was a no-brainer stock during the pandemic. It had unbelievable growth, strong profits, and an incredible outlook, but anyone who bought at elevated levels in late 2020 is down nearly 90% from their initial investment.Palantir's stock hasn't reached near the hubris as Zoom Video's did, but it's still valued at a hefty premium.PLTR PS Ratio data by YChartsAt 21 times sales, its price-to-sales (P/S) ratio is nearly equal to its growth rate. This normally doesn't bode well for a stock, as it indicates incredibly high growth expectations.But is that enough to completely avoid the stock? I don't think so. If investors avoided companies like Amazon or Nvidia because they were too expensive, they'd have missed out on massive winners. However, highly priced stocks can be volatile, so you'll need to set a longer holding period of around five years to make it worth it.If you can do that, then Palantir could be a fantastic AI investment at these levels.","news_type":1},"isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9021630595,"gmtCreate":1653040550717,"gmtModify":1676535213137,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","listText":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","text":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021630595","repostId":"2236030678","repostType":2,"isVote":1,"tweetType":1,"viewCount":281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807702702,"gmtCreate":1628054881506,"gmtModify":1703500380345,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Will the booster jab (3rd jab vaccination)&nbsp;boost the share ptocebof PFE ?","listText":"Will the booster jab (3rd jab vaccination)&nbsp;boost the share ptocebof PFE ?","text":"Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807702702","repostId":"1156524625","repostType":4,"repost":{"id":"1156524625","pubTimestamp":1628053893,"share":"https://ttm.financial/m/news/1156524625?lang=&edition=fundamental","pubTime":"2021-08-04 13:11","market":"us","language":"en","title":"Pfizer hikes 2021 outlook after vaccine boosts sales, profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1156524625","media":"Business Hala","summary":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter ","content":"<p>Strong sales of its COVID-19 vaccine and other drugs helped<b> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.</p>\n<p></p>\n<p>Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.</p>\n<p>Amid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.</p>\n<p>Pfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US</p>\n<p>The New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.</p>\n<p>“We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”</p>\n<p>Bourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.</p>\n<p>By the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.</p>\n<p>The US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.</p>\n<p>Second-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.</p>\n<p>Adjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.</p>\n<p>Its quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.</p>\n<p>Pfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.</p>\n<p>Sales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.</p>\n<p>Pfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.</p>\n<p>In May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.</p>\n<p>Pfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US</p>\n<p>Pfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.</p>\n<p></p>","source":"lsy1627951004805","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer hikes 2021 outlook after vaccine boosts sales, profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer hikes 2021 outlook after vaccine boosts sales, profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 13:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/><strong>Business Hala</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.\n\nStrong sales of its COVID-...</p>\n\n<a href=\"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://businesshala.com/pfizer-hikes-2021-outlook-after-vaccine-boosts-sales-profit/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156524625","content_text":"Strong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit by 59%, beating Wall Street’s expectations.\n\nStrong sales of its COVID-19 vaccine and other drugs helped Pfizer nearly double its second-quarter revenue and boost its profit to 59%, beating Wall Street’s expectations and helping the drug giant look forward to 2021. Helped to rapidly increase sales and profit forecasts.\nAmid the growing coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, generating nearly half of its revenue — $7.84 billion from direct sales and revenue splitting with its partner, Germany’s BioNTech.\nPfizer now forecasts revenue from the two-dose vaccine this year to reach $33.5 billion for the 2.1 billion doses it has been contracted to provide by the end of the year. This does not include the contract signed last week to provide an additional 200 million doses to the US\nThe New York company revealed on Wednesday that an ongoing trial of a booster shot given six months after the second vaccine dose showed that it increased antibody levels against the more-transmissible delta variant to 11 times higher in older people and younger people. increased more than five times. , compared to levels after two doses. The company also released data showing that six months after vaccination, the shots were 97% effective at preventing serious disease.\n“We are absolutely convinced that a booster will be needed,” CEO Albert Boerla said in an interview, “that a third dose of the original vaccine may be sufficient.” Still, in August Pfizer will begin testing a booster targeting the Delta version in volunteers, because “there’s so much at stake, you can’t take the risk.”\nBourla said Pfizer has delivered more than 1 billion doses of the vaccine globally and expects to make 3 billion doses this year, with many more going to low- and middle-income countries. So far, most of the doses of all COVID-19 vaccines produced in Europe and the US have gone to rich countries.\nBy the end of September, trials in 5- to 11-year-old volunteers should produce the safety and efficacy data necessary to obtain emergency use authorization in that age group, and data on trials in children 6 months to 5 years of age should be used. must comply. Soon according to Pfizer.\nThe US Food and Drug Administration is now reviewing data that could lead to full approval of the vaccine for adults, which Borla said could reduce hesitation from vaccination.\nSecond-quarter net income was $5.56 billion, or 98 cents per share, up from $3.49 billion, or 62 cents per share.\nAdjusted earnings, excluding one-time gains and losses, amounted to $6.08 billion, or $1.07 per share, significantly higher than Wall Street’s 97 cents.\nIts quarterly revenue of $18.98 billion is up from last year’s $9.86 billion, and also topped estimates.\nPfizer shares rose $1.46, or 3.5%, to $43.56, near a 52-week high.\nSales of Pfizer’s drugs for cancer and rare diseases, as well as drugs primarily used in hospitals, grew double-digit. Sales of Eliquis for preventing blood clots and stroke rose 16% to $1.48 billion, while Ibrance’s sales rose 4% to $1.4 billion in the quarter.\nPfizer’s pneumonia vaccine Prevnar 13 – the world’s most lucrative vaccine by far – climbed 11% in sales to $1.24 billion amid the pandemic. The company won US approval in June for Prevnar 20, an updated version for adults that protects against seven more strains of pneumococcal disease.\nIn May, Pfizer and partner Myovent received approval for MyFembry to reduce heavy menstrual bleeding due to uterine fibroids in premenopausal women.\nPfizer’s head of research Mikel Dolstein outlined eight major research programs with the potential to have a major impact on public health, including a pill to treat COVID-19 and vaccines against Lyme disease and respiratory syncytial virus, which occur each year. Infects and kills more than 5% of adults. about 15,000 of them in the US\nPfizer now expects adjusted full-year earnings in the range of $3.95 to $4.05 per share, up from its May forecast of $3.55 to $3.65 per share, and revenue in the range of $78 billion to $80 billion. , from $70.5 billion to $72.5 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807706941,"gmtCreate":1628054725583,"gmtModify":1703500377391,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Turn to RED MOON now!","listText":"Turn to RED MOON now!","text":"Turn to RED MOON now!","images":[{"img":"https://static.tigerbbs.com/2ef0259d7e3fb071dde7bf5e6836d5ba","width":"1125","height":"2083"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807706941","isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":807700409,"gmtCreate":1628054431501,"gmtModify":1703500371024,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Toyota! My trusted car","listText":"Toyota! My trusted car","text":"Toyota! My trusted car","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807700409","repostId":"1136976094","repostType":4,"repost":{"id":"1136976094","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628054171,"share":"https://ttm.financial/m/news/1136976094?lang=&edition=fundamental","pubTime":"2021-08-04 13:16","market":"us","language":"en","title":"Toyota posts record $9.2 bln quarterly operating profit on sales rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1136976094","media":"Reuters","summary":"TOKYO, August 4 (Reuters) - Toyota Motor Corp reported on Wednesday a record quarterly operating pro","content":"<p>TOKYO, August 4 (Reuters) - Toyota Motor Corp&nbsp;reported on Wednesday a record quarterly operating profit of 997.49 billion yen ($9.15 billion) as pandemic-hit sales rebounded and it weathered a global chip supply shortage better than many rivals.</p>\n<p>Operating profit at Japan's biggest automaker for the three months ended June 30 was higher than an average estimate of 752 billion yen based on 10 analysts polled by Refinitiv, and well above 13.9 billion in the pandemic-hit first quarter a year earlier.</p>\n<p>Profit for the latest quarter was also boosted by favourable foreign exchange movements.</p>\n<p>However, Toyota maintained its forecast made in May for an operating profit of 2.5 trillion yen for the current fiscal year, citing an uncertain situation due to the spread of the coronavirus in emerging economies, the chip shortage and a higher cost for parts.</p>\n<p>The outlook from the maker of the RAV4 SUV crossover and Prius hybrid vehicles trailed an average forecast for a 2.88 trillion yen operating profit, according to 24 analysts polled by Refinitiv.</p>\n<p>Toyota shares fell 2% in afternoon trading on Wednesday, extending losses from the morning session.</p>\n<p>The company has been stockpiling semiconductors, used in everything from engine maintenance to car safety and entertainment systems, amid a global supply shortage that has hit production at rivals such as Hyundai Motor Co(005380.KS)&nbsp;and Ford Motor Co(F.N).</p>\n<p>Toyota has benefited from a business continuity plan developed in the wake of the Fukushima earthquake in 2011 that required suppliers to stockpile anywhere from two to six months' worth of chips depending on the time it takes from order to delivery, Reuters reported in March.</p>\n<p>But more recently, Toyota has faced production difficulties in Thailand, where it last month suspended vehicle production at three of its manufacturing plants due to a pandemic-related parts shortage.</p>\n<p>The automaker maintained its forecast for 8.7 million vehicle sales in the current fiscal year, up from 7.65 million last year.</p>\n<p>($1 = 109.0500 yen)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toyota posts record $9.2 bln quarterly operating profit on sales rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToyota posts record $9.2 bln quarterly operating profit on sales rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-04 13:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, August 4 (Reuters) - Toyota Motor Corp&nbsp;reported on Wednesday a record quarterly operating profit of 997.49 billion yen ($9.15 billion) as pandemic-hit sales rebounded and it weathered a global chip supply shortage better than many rivals.</p>\n<p>Operating profit at Japan's biggest automaker for the three months ended June 30 was higher than an average estimate of 752 billion yen based on 10 analysts polled by Refinitiv, and well above 13.9 billion in the pandemic-hit first quarter a year earlier.</p>\n<p>Profit for the latest quarter was also boosted by favourable foreign exchange movements.</p>\n<p>However, Toyota maintained its forecast made in May for an operating profit of 2.5 trillion yen for the current fiscal year, citing an uncertain situation due to the spread of the coronavirus in emerging economies, the chip shortage and a higher cost for parts.</p>\n<p>The outlook from the maker of the RAV4 SUV crossover and Prius hybrid vehicles trailed an average forecast for a 2.88 trillion yen operating profit, according to 24 analysts polled by Refinitiv.</p>\n<p>Toyota shares fell 2% in afternoon trading on Wednesday, extending losses from the morning session.</p>\n<p>The company has been stockpiling semiconductors, used in everything from engine maintenance to car safety and entertainment systems, amid a global supply shortage that has hit production at rivals such as Hyundai Motor Co(005380.KS)&nbsp;and Ford Motor Co(F.N).</p>\n<p>Toyota has benefited from a business continuity plan developed in the wake of the Fukushima earthquake in 2011 that required suppliers to stockpile anywhere from two to six months' worth of chips depending on the time it takes from order to delivery, Reuters reported in March.</p>\n<p>But more recently, Toyota has faced production difficulties in Thailand, where it last month suspended vehicle production at three of its manufacturing plants due to a pandemic-related parts shortage.</p>\n<p>The automaker maintained its forecast for 8.7 million vehicle sales in the current fiscal year, up from 7.65 million last year.</p>\n<p>($1 = 109.0500 yen)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TOYOF":"Toyota Motor Corp.","TM":"丰田汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136976094","content_text":"TOKYO, August 4 (Reuters) - Toyota Motor Corp reported on Wednesday a record quarterly operating profit of 997.49 billion yen ($9.15 billion) as pandemic-hit sales rebounded and it weathered a global chip supply shortage better than many rivals.\nOperating profit at Japan's biggest automaker for the three months ended June 30 was higher than an average estimate of 752 billion yen based on 10 analysts polled by Refinitiv, and well above 13.9 billion in the pandemic-hit first quarter a year earlier.\nProfit for the latest quarter was also boosted by favourable foreign exchange movements.\nHowever, Toyota maintained its forecast made in May for an operating profit of 2.5 trillion yen for the current fiscal year, citing an uncertain situation due to the spread of the coronavirus in emerging economies, the chip shortage and a higher cost for parts.\nThe outlook from the maker of the RAV4 SUV crossover and Prius hybrid vehicles trailed an average forecast for a 2.88 trillion yen operating profit, according to 24 analysts polled by Refinitiv.\nToyota shares fell 2% in afternoon trading on Wednesday, extending losses from the morning session.\nThe company has been stockpiling semiconductors, used in everything from engine maintenance to car safety and entertainment systems, amid a global supply shortage that has hit production at rivals such as Hyundai Motor Co(005380.KS) and Ford Motor Co(F.N).\nToyota has benefited from a business continuity plan developed in the wake of the Fukushima earthquake in 2011 that required suppliers to stockpile anywhere from two to six months' worth of chips depending on the time it takes from order to delivery, Reuters reported in March.\nBut more recently, Toyota has faced production difficulties in Thailand, where it last month suspended vehicle production at three of its manufacturing plants due to a pandemic-related parts shortage.\nThe automaker maintained its forecast for 8.7 million vehicle sales in the current fiscal year, up from 7.65 million last year.\n($1 = 109.0500 yen)","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807477898,"gmtCreate":1628054319814,"gmtModify":1703500369870,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Inari has good prospect! At 18x is a good bargain","listText":"Inari has good prospect! At 18x is a good bargain","text":"Inari has good prospect! At 18x is a good bargain","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/807477898","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","pubTimestamp":1628045612,"share":"https://ttm.financial/m/news/1124757232?lang=&edition=fundamental","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Pfizer might surprise to the upside.</li>\n <li>Inari Medical is growing like gangbusters.</li>\n <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li>\n</ul>\n<p>COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p>\n<p>A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<h3><b>Pfizer: More room to run</b></h3>\n<p><b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p>\n<p>Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p>\n<p>There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p>\n<p>Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p>\n<p>The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p>\n<p>Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p>\n<h3><b>Inari Medical: Skyrocketing Sales</b></h3>\n<p><b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p>\n<p>This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p>\n<p>Not to mention the company's results thus far for blood clots in the lung are spectacular:</p>\n<ul>\n <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>\n <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>\n <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>\n <li>No ICU stays are required after the procedure.</li>\n</ul>\n<p>Add it all up, and Inari's retrieval device seems like an obvious choice.</p>\n<p>The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p>\n<p>Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p>\n<h3><b>Novavax: How high can it go?</b></h3>\n<p><b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p>\n<p>Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p>\n<p>Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p>\n<p>In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p>\n<p>Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 10:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NARI":"Inari Medical, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":481,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803293762,"gmtCreate":1627439678656,"gmtModify":1703489992445,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Anyone drinking beers","listText":"Anyone drinking beers","text":"Anyone drinking beers","images":[{"img":"https://static.tigerbbs.com/2bfc4834d8c3e481cb02a247326c4a8f","width":"1125","height":"2793"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803293762","isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":809384115,"gmtCreate":1627348416737,"gmtModify":1703488044503,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Nice beer, Samual Adam","listText":"Nice beer, Samual Adam","text":"Nice beer, Samual Adam","images":[{"img":"https://static.tigerbbs.com/8c81143c8d7d05e9c1d1bf9c10749ede","width":"1125","height":"2629"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809384115","isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":178477161,"gmtCreate":1626834797553,"gmtModify":1703766101583,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178477161","repostId":"2153761308","repostType":2,"repost":{"id":"2153761308","pubTimestamp":1626834023,"share":"https://ttm.financial/m/news/2153761308?lang=&edition=fundamental","pubTime":"2021-07-21 10:20","market":"hk","language":"zh","title":"奈雪的茶跌近4% 较招股价已跌超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2153761308","media":"新浪港股","summary":"7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/newchart/hk_stock/min_660/02150.gif\"/>\n</div>\n</div>\n<p>　　7月21日消息，<span><a href=\"https://laohu8.com/S/02150\">奈雪的茶</a></span><span></span>持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。</p>\n<p>　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在<a href=\"https://laohu8.com/S/SINA\">新浪</a>财经APP</div>\n</div>\n</div></body></html>","source":"highlight_sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>奈雪的茶跌近4% 较招股价已跌超35%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n奈雪的茶跌近4% 较招股价已跌超35%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 10:20 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/67b872f6d508e7d70db55d570f1b762b","relate_stocks":{"02150":"奈雪的茶"},"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2021-07-21/doc-ikqciyzk6703448.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2153761308","content_text":"7月21日消息，奈雪的茶持续下跌，现跌3.82%，报13.08港元，最新市值224.34亿港元。\n　　奈雪的茶于6月30日首挂上市，每股定价19.8港元。上市当日破发，此后股价持续下行，今日再度跌近4%，低见12.86港元，较招股价已跌超35%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","news_type":1},"isVote":1,"tweetType":1,"viewCount":653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178473966,"gmtCreate":1626834447955,"gmtModify":1703766092504,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"What about Nio; Xpeng Lucid etc etc ?","listText":"What about Nio; Xpeng Lucid etc etc ?","text":"What about Nio; Xpeng Lucid etc etc ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178473966","repostId":"1110113604","repostType":4,"isVote":1,"tweetType":1,"viewCount":442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178447118,"gmtCreate":1626834329134,"gmtModify":1703766088604,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"What happen to Blue zmoon? Turning to Red Moon now","listText":"What happen to Blue zmoon? Turning to Red Moon now","text":"What happen to Blue zmoon? Turning to Red Moon now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/178447118","repostId":"2153137486","repostType":4,"repost":{"id":"2153137486","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626833848,"share":"https://ttm.financial/m/news/2153137486?lang=&edition=fundamental","pubTime":"2021-07-21 10:17","market":"hk","language":"en","title":"HK-listed Blue Moon Group hits record low as co forecasts H1 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2153137486","media":"Reuters","summary":"** Shares of Chinese detergent maker Blue Moon Group Holdings Ltd fall 8.5% to HK$7.60, their lowest","content":"<p>** Shares of Chinese detergent maker Blue Moon Group Holdings Ltd fall 8.5% to HK$7.60, their lowest since listing on Dec 16, and on course for sixth straight decline</p>\n<p>** Stock is biggest percentage decliner in the Hang Seng Composite Index and among the 30 biggest percentage decliner on the Hong Kong bourse</p>\n<p>** The Guangdong-based company expects to post a net loss of HK$44 mln ($5.7 mln) in H1, from HK$302 mln profit a year earlier, amid oversupply of lower-priced products by platforms disrupting its pricing strategy, and higher material costs</p>\n<p>** Brokerage Daiwa downgrades Blue Moon to \"underperform\" from \"buy\" and trims TP to HK$7 from HK$17.40, on significant deterioration in gross margin and unexpected loss-making in H1 on product price discounts and higher raw-material costs</p>\n<p>** The Hong Kong composite Industry Index tracking consumer staples gains 0.5%, and the material index rises 1.3%</p>\n<p>** The Hang Seng Composite Index gains 0.2%</p>\n<p>** The Hang Seng China Enterprises Index climbs 0.1%, while the benchmark index slips 0.1%</p>\n<p>** Stock down 45.5% this year, as of last close</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK-listed Blue Moon Group hits record low as co forecasts H1 loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK-listed Blue Moon Group hits record low as co forecasts H1 loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-21 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Chinese detergent maker Blue Moon Group Holdings Ltd fall 8.5% to HK$7.60, their lowest since listing on Dec 16, and on course for sixth straight decline</p>\n<p>** Stock is biggest percentage decliner in the Hang Seng Composite Index and among the 30 biggest percentage decliner on the Hong Kong bourse</p>\n<p>** The Guangdong-based company expects to post a net loss of HK$44 mln ($5.7 mln) in H1, from HK$302 mln profit a year earlier, amid oversupply of lower-priced products by platforms disrupting its pricing strategy, and higher material costs</p>\n<p>** Brokerage Daiwa downgrades Blue Moon to \"underperform\" from \"buy\" and trims TP to HK$7 from HK$17.40, on significant deterioration in gross margin and unexpected loss-making in H1 on product price discounts and higher raw-material costs</p>\n<p>** The Hong Kong composite Industry Index tracking consumer staples gains 0.5%, and the material index rises 1.3%</p>\n<p>** The Hang Seng Composite Index gains 0.2%</p>\n<p>** The Hang Seng China Enterprises Index climbs 0.1%, while the benchmark index slips 0.1%</p>\n<p>** Stock down 45.5% this year, as of last close</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"06993":"蓝月亮集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153137486","content_text":"** Shares of Chinese detergent maker Blue Moon Group Holdings Ltd fall 8.5% to HK$7.60, their lowest since listing on Dec 16, and on course for sixth straight decline\n** Stock is biggest percentage decliner in the Hang Seng Composite Index and among the 30 biggest percentage decliner on the Hong Kong bourse\n** The Guangdong-based company expects to post a net loss of HK$44 mln ($5.7 mln) in H1, from HK$302 mln profit a year earlier, amid oversupply of lower-priced products by platforms disrupting its pricing strategy, and higher material costs\n** Brokerage Daiwa downgrades Blue Moon to \"underperform\" from \"buy\" and trims TP to HK$7 from HK$17.40, on significant deterioration in gross margin and unexpected loss-making in H1 on product price discounts and higher raw-material costs\n** The Hong Kong composite Industry Index tracking consumer staples gains 0.5%, and the material index rises 1.3%\n** The Hang Seng Composite Index gains 0.2%\n** The Hang Seng China Enterprises Index climbs 0.1%, while the benchmark index slips 0.1%\n** Stock down 45.5% this year, as of last close","news_type":1},"isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171610471,"gmtCreate":1626741415893,"gmtModify":1703764176642,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Chewy! Chewy!","listText":"Chewy! Chewy!","text":"Chewy! Chewy!","images":[{"img":"https://static.tigerbbs.com/f02a25ede97c39da8a92b841931a4183","width":"1125","height":"2425"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171610471","isVote":1,"tweetType":1,"viewCount":71,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143853115,"gmtCreate":1625788900337,"gmtModify":1703748465046,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Worth researching Abbots&nbsp;","listText":"Worth researching Abbots&nbsp;","text":"Worth researching Abbots","images":[{"img":"https://static.tigerbbs.com/b9816c04b35845a61d22ae23b98fae62","width":"1125","height":"2069"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143853115","isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143090484,"gmtCreate":1625751710148,"gmtModify":1703747806328,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"When is the right timing to enter?","listText":"When is the right timing to enter?","text":"When is the right timing to enter?","images":[{"img":"https://static.tigerbbs.com/294a6040baa314b1cd484be55f7866f2","width":"1125","height":"2412"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143090484","isVote":1,"tweetType":1,"viewCount":121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143004853,"gmtCreate":1625751654172,"gmtModify":1703747802596,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Almost become a cinema giants&nbsp;","listText":"Almost become a cinema giants&nbsp;","text":"Almost become a cinema giants","images":[{"img":"https://static.tigerbbs.com/928369ace60bca0c682b3944162903fd","width":"1125","height":"2330"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143004853","isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":153853768,"gmtCreate":1625018518454,"gmtModify":1703850222383,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02150\">$NAYUKI(02150)$</a>?","listText":"<a href=\"https://laohu8.com/S/02150\">$NAYUKI(02150)$</a>?","text":"$NAYUKI(02150)$?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153853768","isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159071113,"gmtCreate":1624933393532,"gmtModify":1703848272356,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"?‍?","listText":"?‍?","text":"?‍?","images":[{"img":"https://static.tigerbbs.com/3a7e58c33f9a85496fc98b1f4e7337b8","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159071113","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":121601346,"gmtCreate":1624460364385,"gmtModify":1703837503192,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/121601346","repostId":"1198462718","repostType":4,"repost":{"id":"1198462718","pubTimestamp":1624448358,"share":"https://ttm.financial/m/news/1198462718?lang=&edition=fundamental","pubTime":"2021-06-23 19:39","market":"us","language":"en","title":"Why U.S. stocks face a tough decade ahead even if corporate revenues are strong","url":"https://stock-news.laohu8.com/highlight/detail?id=1198462718","media":"MarketWatch","summary":"Stock market’s return will grow at the same rate as the U.S. economy.\n\nMight there be hope, after al","content":"<blockquote>\n <b>Stock market’s return will grow at the same rate as the U.S. economy.</b>\n</blockquote>\n<p>Might there be hope, after all, for the U.S. stock market’s return over the next decade? I ask as a follow up tomy column earlier this monthin which I concluded that even under optimistic assumptions, the S&amp;P 500SPX,+0.51%over the next 10 years is unlikely to produce an annualized total real return greater than the low single-digits.</p>\n<p>My argument was that the stock market will not be able to count on the three pillars that have propped it up over the past decade — increasing valuations, profit margins and more buybacks than new shares issued (net buybacks).</p>\n<p>Some readers responded that I had overlooked an escape hatch which would enable the market to produce decent returns: corporate revenues can grow faster than the overall U.S. economy. To the extent this is so, then the stock market does not need any of those three pillars to do well.</p>\n<p>This escape hatch appears to have solid evidence behind it. Consider a recent note to clients from Jonathan Golub, chief U.S. equity strategist and head of quantitative research at Credit Suisse. He reported that, according to an econometric model he constructed based on S&amp;P 500 sales and GDP since 2000, “every 1% upside in nominal GDP drives 2½–3% improvement in revenues.”</p>\n<p>If so, this certainly would be good for stock investors. It would mean that even without increasing valuations, profit margins or net buybacks, the stock market could significantly outperform the overall economy.</p>\n<p>Unfortunately, this argument is too good to be true. I analyzed S&amp;P 500 sales back to the early 1970s (courtesy of data from Ned Davis Research), and found almost a 1:1 correlation between sales growth and GDP growth.</p>\n<p>This is entirely what we should expect, according to Robert Arnott, chairman and founder of Research Affiliates. In an email, he said that “aggregate sales should offer a pretty clean 1:1 relationship to GDP. Any other ratio makes no sense on a sustained basis.”</p>\n<p>How then did Golub come up with such a different answer? My hunch is that it traces to how he measured sales. In an email, Golub’s colleague Manish Bangard, an equity strategist at Credit Suisse, explained that they focused on sales per share. But, as Arnott points out, this per-share number reflects the impact of net buybacks. So the high sales-to-GDP ratio that Golub reports is not a pure measure of how sales growth relates to GDP. (I did not receive a response to my requests for additional comment.)</p>\n<p><b>Investment implication</b></p>\n<p>The implication is that we should not expect the U.S. stock market over the next decade to grow faster than the economy. It may in fact grow much more slowly if P/E ratios or profit margins regress even partway to their historical mean, or if net buybacks turn out to be negative (as they’ve been for most of U.S. history).</p>\n<p>But even if P/E ratios and profit margins stay constant between now and 2031 and there are no net buybacks, the lesson of history is that the U.S. market will grow no faster than the economy.</p>\n<p>Consider what that means. TheCongressional Budget Office is projectingthat real GDP from 2022 through 2031 will grow at a 1.8% annualized rate. Even that may be optimistic, because the CBO projects no recession between now and then.</p>\n<p>The bottom line: The stock market has its work cut out to produce even a fraction of the past decade’s fabulous return.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why U.S. stocks face a tough decade ahead even if corporate revenues are strong</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy U.S. stocks face a tough decade ahead even if corporate revenues are strong\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 19:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/why-u-s-stocks-face-a-tough-decade-ahead-even-if-corporate-revenues-are-strong-11624429824?siteid=yhoof2><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stock market’s return will grow at the same rate as the U.S. economy.\n\nMight there be hope, after all, for the U.S. stock market’s return over the next decade? I ask as a follow up tomy column earlier...</p>\n\n<a href=\"https://www.marketwatch.com/story/why-u-s-stocks-face-a-tough-decade-ahead-even-if-corporate-revenues-are-strong-11624429824?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/why-u-s-stocks-face-a-tough-decade-ahead-even-if-corporate-revenues-are-strong-11624429824?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198462718","content_text":"Stock market’s return will grow at the same rate as the U.S. economy.\n\nMight there be hope, after all, for the U.S. stock market’s return over the next decade? I ask as a follow up tomy column earlier this monthin which I concluded that even under optimistic assumptions, the S&P 500SPX,+0.51%over the next 10 years is unlikely to produce an annualized total real return greater than the low single-digits.\nMy argument was that the stock market will not be able to count on the three pillars that have propped it up over the past decade — increasing valuations, profit margins and more buybacks than new shares issued (net buybacks).\nSome readers responded that I had overlooked an escape hatch which would enable the market to produce decent returns: corporate revenues can grow faster than the overall U.S. economy. To the extent this is so, then the stock market does not need any of those three pillars to do well.\nThis escape hatch appears to have solid evidence behind it. Consider a recent note to clients from Jonathan Golub, chief U.S. equity strategist and head of quantitative research at Credit Suisse. He reported that, according to an econometric model he constructed based on S&P 500 sales and GDP since 2000, “every 1% upside in nominal GDP drives 2½–3% improvement in revenues.”\nIf so, this certainly would be good for stock investors. It would mean that even without increasing valuations, profit margins or net buybacks, the stock market could significantly outperform the overall economy.\nUnfortunately, this argument is too good to be true. I analyzed S&P 500 sales back to the early 1970s (courtesy of data from Ned Davis Research), and found almost a 1:1 correlation between sales growth and GDP growth.\nThis is entirely what we should expect, according to Robert Arnott, chairman and founder of Research Affiliates. In an email, he said that “aggregate sales should offer a pretty clean 1:1 relationship to GDP. Any other ratio makes no sense on a sustained basis.”\nHow then did Golub come up with such a different answer? My hunch is that it traces to how he measured sales. In an email, Golub’s colleague Manish Bangard, an equity strategist at Credit Suisse, explained that they focused on sales per share. But, as Arnott points out, this per-share number reflects the impact of net buybacks. So the high sales-to-GDP ratio that Golub reports is not a pure measure of how sales growth relates to GDP. (I did not receive a response to my requests for additional comment.)\nInvestment implication\nThe implication is that we should not expect the U.S. stock market over the next decade to grow faster than the economy. It may in fact grow much more slowly if P/E ratios or profit margins regress even partway to their historical mean, or if net buybacks turn out to be negative (as they’ve been for most of U.S. history).\nBut even if P/E ratios and profit margins stay constant between now and 2031 and there are no net buybacks, the lesson of history is that the U.S. market will grow no faster than the economy.\nConsider what that means. TheCongressional Budget Office is projectingthat real GDP from 2022 through 2031 will grow at a 1.8% annualized rate. Even that may be optimistic, because the CBO projects no recession between now and then.\nThe bottom line: The stock market has its work cut out to produce even a fraction of the past decade’s fabulous return.","news_type":1},"isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167784825,"gmtCreate":1624285036867,"gmtModify":1703832491861,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Will the drop ripple to Lithium and battery stock as well?","listText":"Will the drop ripple to Lithium and battery stock as well?","text":"Will the drop ripple to Lithium and battery stock as well?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/167784825","repostId":"1136791321","repostType":4,"repost":{"id":"1136791321","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624282996,"share":"https://ttm.financial/m/news/1136791321?lang=&edition=fundamental","pubTime":"2021-06-21 21:43","market":"us","language":"en","title":"EV stocks fell in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1136791321","media":"Tiger Newspress","summary":"(June 21) EV stocks fell in morning trading.","content":"<p>(June 21)&nbsp;EV stocks fell in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e7e7cf675e122ca02f2d220cde025a88\" tg-width=\"310\" tg-height=\"239\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;EV stocks fell in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e7e7cf675e122ca02f2d220cde025a88\" tg-width=\"310\" tg-height=\"239\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","NIO":"蔚来","TSLA":"特斯拉","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136791321","content_text":"(June 21) EV stocks fell in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164301790,"gmtCreate":1624169440910,"gmtModify":1703830072504,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164301790","repostId":"1199331995","repostType":4,"repost":{"id":"1199331995","pubTimestamp":1624065374,"share":"https://ttm.financial/m/news/1199331995?lang=&edition=fundamental","pubTime":"2021-06-19 09:16","market":"us","language":"en","title":"U.S. IPO Week Ahead: Billion-Dollar Deals Come To Market In A 12 IPO Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1199331995","media":"Renaissance","summary":"12 IPOs are scheduled to raise $5.6 billion in the week ahead led by two billion-dollar deals.Chinese freight platform Full Truck Alliance plans to raise $1.5 billion at a $19.7 billion market cap. The company’s platform connects shippers with truckers to facilitate shipments across distance ranges, cargo weights, and types. Full Truck states that it is the world's largest digital freight platform by gross transaction value , facilitating 22+ million fulfilled orders with GTV of nearly $8 billio","content":"<p>12 IPOs are scheduled to raise $5.6 billion in the week ahead led by two billion-dollar deals.</p>\n<p>Chinese freight platform&nbsp;<b>Full Truck Alliance</b>(YMM) plans to raise $1.5 billion at a $19.7 billion market cap. The company’s platform connects shippers with truckers to facilitate shipments across distance ranges, cargo weights, and types. Full Truck states that it is the world's largest digital freight platform by gross transaction value (GTV), facilitating 22+ million fulfilled orders with GTV of nearly $8 billion in the 1Q21.</p>\n<p>Healthcare manager&nbsp;<b>Bright Health Group</b>(BHG) plans to raise $1.3 billion at a $15.4 billion market cap. Bright Health seeks to employ a more consumer-centric approach to healthcare to improve consumer experiences. Through a multi-pronged organic and inorganic growth strategy, the company’s core business has grown to serve roughly 623,000 patients in 14 states since its founding.</p>\n<p>Data infrastructure provider&nbsp;<b>Confluent</b>(CFLT) plans to raise $713 million at a $10.0 billion market cap. Confluent data infrastructure offering is designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. The company had more than 2,500 customers as of March 2021, with a dollar-based net retention rate of 117%.</p>\n<p>Car wash brand&nbsp;<b>Mister Car Wash</b>(MCW) plans to raise $600 million at a $5.3 billion market cap. Profitable with solid cash flow, Mister Car Wash is the largest national car wash brand in the US, with 344 locations in 21 states. The company offers a monthly subscription program called Unlimited Wash Club which had 1.4 million members as of 3/31/21, representing nearly two-thirds of total wash sales.</p>\n<p>Digital physicians network&nbsp;<b>Doximity</b>(DOCS) plans to raise $501 million at a $4.5 billion market cap. Doximity claims that it is the leading digital platform for US medical professionals, allowing collaboration with colleagues and secure coordination of patient care, among other features. Fast growing and profitable, the company had over 1.8 million members as of 3/31/21, representing more than 80% of physicians across the country.</p>\n<p>Customer experience software provider&nbsp;<b>Sprinklr</b>(CXM) plans to raise $361 million at a $5.5 billion market cap. Sprinklr provides a software platform that helps enterprises create a persistent, unified view of each customer at scale. The company has attracted more than 1,000 customers, including over 50% of the Fortune 100. Sprinklr has improved its gross margins, though cash flow swung negative in 1Q FY22.</p>\n<p>HR platform provider&nbsp;<b>First Advantage</b>(FA) plans to raise $298 million at a $2.1 billion market cap. First Advantage provides technology solutions for screening, verifications, safety, and compliance related to human capital. Profitable with positive cash flow, the company derives most of its revenues from pre-onboarding screening, performing over 75 million screens on behalf of more than 30,000 customers in 2020.</p>\n<p>Chinese social networking platform&nbsp;<b>Soulgate</b>(SSR) plans to raise $185 million at a $1.8 billion market cap. The company’s app Soul is a virtual social network created to address the drawbacks of current social media platforms. In March 2021, the company averaged 9.1 million DAUs, a 94% increase over the prior year period.</p>\n<p>Digital financial services provider&nbsp;<b>AMTD Digital</b>(HKD) plans to raise $120 million at a $1.4 billion market cap. AMTD Digital states that it is the \"fusion reactor\" at the core of the AMTD SpiderNet ecosystem, operating a comprehensive digital solutions platform in Asia. Profitable with explosive growth, the company primarily generates revenue from fees and commissions in two lines of business.</p>\n<p>Organ bioengineering company&nbsp;<b>Miromatrix Medical</b>(MIRO) plans to raise $32 million at a $162 million market cap. Miromatrix is developing a novel technology for bioengineering fully transplantable human organs, initially focused on livers and kidneys. The company has demonstrated functional vasculature and important organ function in preclinical studies, and hopes to initiate a Phase 1 trial in late 2022 with its External Liver Assist Product.</p>\n<p>Kidney disease biotech&nbsp;<b>Unicycive Therapeutics</b>(UNCY) plans to raise $25 million at a $116 million market cap. The company’s candidates include Renazorb, which was in-licensed from Spectrum Pharmaceuticals, and UNI 494, which was in-licensed from Sphaera Pharmaceuticals. Unicycive began conducting preclinical trials on UNI 494 in 2020.</p>\n<p>Antibiotic biotech&nbsp;<b>Acurx Pharmaceuticals</b>(ACXP) plans to raise $15 million at a $62 million market cap. The company is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the WHO, CDC, and USDA. Its lead candidate recently completed a Phase 2a trial in patients with C. difficile infections, and is expected to begin a Phase 2b trial this year.</p>\n<table>\n <tbody>\n  <tr>\n   <th>U.S. IPO Calendar</th>\n  </tr>\n  <tr>\n   <th>Issuer Business</th>\n   <th>Deal Size Market Cap</th>\n   <th>Price Range Shares Filed</th>\n   <th>Top Bookrunners</th>\n  </tr>\n  <tr>\n   <td><p>Full Truck Alliance (YMM)</p><p>Guiyang, China</p></td>\n   <td>$1,485M$19,723M</td>\n   <td>$17 - $1982,500,000</td>\n   <td>Morgan StanleyCICC</td>\n  </tr>\n  <tr>\n   <td>Digital freight platform that connects shippers and truckers in China.</td>\n  </tr>\n  <tr>\n   <td><p>First Advantage (FA)</p><p>Atlanta, GA</p></td>\n   <td>$298M$2,097M</td>\n   <td>$13 - $1521,250,000</td>\n   <td>BarclaysBofA</td>\n  </tr>\n  <tr>\n   <td>Provides background checks and other services to corporate customers.</td>\n  </tr>\n  <tr>\n   <td><p>Sprinklr (CXM)</p><p>New York, NY</p></td>\n   <td>$361M$5,541M</td>\n   <td>$18 - $2019,000,000</td>\n   <td>Morgan StanleyJP Morgan</td>\n  </tr>\n  <tr>\n   <td>Provides customer experience management software for enterprises.</td>\n  </tr>\n  <tr>\n   <td><p>Bright Health Group (BHG)</p><p>Minneapolis, MN</p></td>\n   <td>$1,290M$15,385M</td>\n   <td>$20 - $2360,000,000</td>\n   <td>JP MorganGoldman</td>\n  </tr>\n  <tr>\n   <td>Provides health insurance and other healthcare services.</td>\n  </tr>\n  <tr>\n   <td><p>Confluent (CFLT)</p><p>Mountain View, CA</p></td>\n   <td>$713M$10,033M</td>\n   <td>$29 - $3323,000,000</td>\n   <td>Morgan StanleyJP Morgan</td>\n  </tr>\n  <tr>\n   <td>Provides an enterprise platform that collects and processes real-time data streams.</td>\n  </tr>\n  <tr>\n   <td><p>Doximity (DOCS)</p><p>San Francisco, CA</p></td>\n   <td>$501M$4,549M</td>\n   <td>$20 - $2323,300,000</td>\n   <td>Morgan StanleyGoldman</td>\n  </tr>\n  <tr>\n   <td>Professional network for physicians with telehealth and scheduling tools.</td>\n  </tr>\n  <tr>\n   <td><p>Soulgate (SSR)</p><p>Shanghai, China</p></td>\n   <td>$185M$1,824M</td>\n   <td>$13 - $1513,200,000</td>\n   <td>Morgan StanleyJefferies</td>\n  </tr>\n  <tr>\n   <td>Provides the gamified social networking app Soul in China.</td>\n  </tr>\n  <tr>\n   <td><p>Acurx Pharmaceuticals (ACXP)</p><p>Staten Island, NY</p></td>\n   <td>$15M$62M</td>\n   <td>$5 - $72,500,000</td>\n   <td>Alexander CapitalNetwork 1</td>\n  </tr>\n  <tr>\n   <td>Phase 2 biotech developing antibiotics for antibiotic-resistant pathogens.</td>\n  </tr>\n  <tr>\n   <td><p>Mister Car Wash (MCW)</p><p>Tucson, AZ</p></td>\n   <td>$600M$5,256M</td>\n   <td>$15 - $1737,500,000</td>\n   <td>BofAMorgan Stanley</td>\n  </tr>\n  <tr>\n   <td>Leading national car wash brand with 344 locations across the US.</td>\n  </tr>\n  <tr>\n   <td><p>AMTD Digital (HKD)</p><p>Hong Kong, China</p></td>\n   <td>$120M$1,388M</td>\n   <td>$6.80 - $8.2016,000,000</td>\n   <td>AMTD GlobalLoop Capital</td>\n  </tr>\n  <tr>\n   <td>Digital financial services provider being spun out of AMTD.</td>\n  </tr>\n  <tr>\n   <td><p>Miromatrix Medical (MIRO)</p><p>Eden Prairie, MN</p></td>\n   <td>$32M$162M</td>\n   <td>$7 - $94,000,000</td>\n   <td>Craig-Hallum</td>\n  </tr>\n  <tr>\n   <td>Developing novel bioengineering technology for organ transplants.</td>\n  </tr>\n  <tr>\n   <td><p>Unicycive Therapeutics (UNCY)</p><p>Los Altos, CA</p></td>\n   <td>$25M$116M</td>\n   <td>$8.50 - $10.502,635,000</td>\n   <td>Roth Cap.</td>\n  </tr>\n  <tr>\n   <td>Early-stage biotech developing in-licensed therapies for kidney disease.</td>\n  </tr>\n </tbody>\n</table>\n<p>Street research is expected for seven companies, and lock-up periods will be expiring for up to two companies.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. IPO Week Ahead: Billion-Dollar Deals Come To Market In A 12 IPO Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. IPO Week Ahead: Billion-Dollar Deals Come To Market In A 12 IPO Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-19 09:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4435613-us-ipo-week-ahead-billion-dollar-deals-come-to-market-in-a-12-ipo-week><strong>Renaissance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12 IPOs are scheduled to raise $5.6 billion in the week ahead led by two billion-dollar deals.\nChinese freight platform Full Truck Alliance(YMM) plans to raise $1.5 billion at a $19.7 billion market ...</p>\n\n<a href=\"https://seekingalpha.com/article/4435613-us-ipo-week-ahead-billion-dollar-deals-come-to-market-in-a-12-ipo-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"YMM":"满帮","DOCS":"Doximity, Inc.","MCW":"Mister Car Wash, Inc.","FA":"First Advantage Corp.","CXM":"Sprinklr, Inc.","CFLT":"Confluent, Inc."},"source_url":"https://seekingalpha.com/article/4435613-us-ipo-week-ahead-billion-dollar-deals-come-to-market-in-a-12-ipo-week","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1199331995","content_text":"12 IPOs are scheduled to raise $5.6 billion in the week ahead led by two billion-dollar deals.\nChinese freight platform Full Truck Alliance(YMM) plans to raise $1.5 billion at a $19.7 billion market cap. The company’s platform connects shippers with truckers to facilitate shipments across distance ranges, cargo weights, and types. Full Truck states that it is the world's largest digital freight platform by gross transaction value (GTV), facilitating 22+ million fulfilled orders with GTV of nearly $8 billion in the 1Q21.\nHealthcare manager Bright Health Group(BHG) plans to raise $1.3 billion at a $15.4 billion market cap. Bright Health seeks to employ a more consumer-centric approach to healthcare to improve consumer experiences. Through a multi-pronged organic and inorganic growth strategy, the company’s core business has grown to serve roughly 623,000 patients in 14 states since its founding.\nData infrastructure provider Confluent(CFLT) plans to raise $713 million at a $10.0 billion market cap. Confluent data infrastructure offering is designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. The company had more than 2,500 customers as of March 2021, with a dollar-based net retention rate of 117%.\nCar wash brand Mister Car Wash(MCW) plans to raise $600 million at a $5.3 billion market cap. Profitable with solid cash flow, Mister Car Wash is the largest national car wash brand in the US, with 344 locations in 21 states. The company offers a monthly subscription program called Unlimited Wash Club which had 1.4 million members as of 3/31/21, representing nearly two-thirds of total wash sales.\nDigital physicians network Doximity(DOCS) plans to raise $501 million at a $4.5 billion market cap. Doximity claims that it is the leading digital platform for US medical professionals, allowing collaboration with colleagues and secure coordination of patient care, among other features. Fast growing and profitable, the company had over 1.8 million members as of 3/31/21, representing more than 80% of physicians across the country.\nCustomer experience software provider Sprinklr(CXM) plans to raise $361 million at a $5.5 billion market cap. Sprinklr provides a software platform that helps enterprises create a persistent, unified view of each customer at scale. The company has attracted more than 1,000 customers, including over 50% of the Fortune 100. Sprinklr has improved its gross margins, though cash flow swung negative in 1Q FY22.\nHR platform provider First Advantage(FA) plans to raise $298 million at a $2.1 billion market cap. First Advantage provides technology solutions for screening, verifications, safety, and compliance related to human capital. Profitable with positive cash flow, the company derives most of its revenues from pre-onboarding screening, performing over 75 million screens on behalf of more than 30,000 customers in 2020.\nChinese social networking platform Soulgate(SSR) plans to raise $185 million at a $1.8 billion market cap. The company’s app Soul is a virtual social network created to address the drawbacks of current social media platforms. In March 2021, the company averaged 9.1 million DAUs, a 94% increase over the prior year period.\nDigital financial services provider AMTD Digital(HKD) plans to raise $120 million at a $1.4 billion market cap. AMTD Digital states that it is the \"fusion reactor\" at the core of the AMTD SpiderNet ecosystem, operating a comprehensive digital solutions platform in Asia. Profitable with explosive growth, the company primarily generates revenue from fees and commissions in two lines of business.\nOrgan bioengineering company Miromatrix Medical(MIRO) plans to raise $32 million at a $162 million market cap. Miromatrix is developing a novel technology for bioengineering fully transplantable human organs, initially focused on livers and kidneys. The company has demonstrated functional vasculature and important organ function in preclinical studies, and hopes to initiate a Phase 1 trial in late 2022 with its External Liver Assist Product.\nKidney disease biotech Unicycive Therapeutics(UNCY) plans to raise $25 million at a $116 million market cap. The company’s candidates include Renazorb, which was in-licensed from Spectrum Pharmaceuticals, and UNI 494, which was in-licensed from Sphaera Pharmaceuticals. Unicycive began conducting preclinical trials on UNI 494 in 2020.\nAntibiotic biotech Acurx Pharmaceuticals(ACXP) plans to raise $15 million at a $62 million market cap. The company is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the WHO, CDC, and USDA. Its lead candidate recently completed a Phase 2a trial in patients with C. difficile infections, and is expected to begin a Phase 2b trial this year.\n\n\n\nU.S. IPO Calendar\n\n\nIssuer Business\nDeal Size Market Cap\nPrice Range Shares Filed\nTop Bookrunners\n\n\nFull Truck Alliance (YMM)Guiyang, China\n$1,485M$19,723M\n$17 - $1982,500,000\nMorgan StanleyCICC\n\n\nDigital freight platform that connects shippers and truckers in China.\n\n\nFirst Advantage (FA)Atlanta, GA\n$298M$2,097M\n$13 - $1521,250,000\nBarclaysBofA\n\n\nProvides background checks and other services to corporate customers.\n\n\nSprinklr (CXM)New York, NY\n$361M$5,541M\n$18 - $2019,000,000\nMorgan StanleyJP Morgan\n\n\nProvides customer experience management software for enterprises.\n\n\nBright Health Group (BHG)Minneapolis, MN\n$1,290M$15,385M\n$20 - $2360,000,000\nJP MorganGoldman\n\n\nProvides health insurance and other healthcare services.\n\n\nConfluent (CFLT)Mountain View, CA\n$713M$10,033M\n$29 - $3323,000,000\nMorgan StanleyJP Morgan\n\n\nProvides an enterprise platform that collects and processes real-time data streams.\n\n\nDoximity (DOCS)San Francisco, CA\n$501M$4,549M\n$20 - $2323,300,000\nMorgan StanleyGoldman\n\n\nProfessional network for physicians with telehealth and scheduling tools.\n\n\nSoulgate (SSR)Shanghai, China\n$185M$1,824M\n$13 - $1513,200,000\nMorgan StanleyJefferies\n\n\nProvides the gamified social networking app Soul in China.\n\n\nAcurx Pharmaceuticals (ACXP)Staten Island, NY\n$15M$62M\n$5 - $72,500,000\nAlexander CapitalNetwork 1\n\n\nPhase 2 biotech developing antibiotics for antibiotic-resistant pathogens.\n\n\nMister Car Wash (MCW)Tucson, AZ\n$600M$5,256M\n$15 - $1737,500,000\nBofAMorgan Stanley\n\n\nLeading national car wash brand with 344 locations across the US.\n\n\nAMTD Digital (HKD)Hong Kong, China\n$120M$1,388M\n$6.80 - $8.2016,000,000\nAMTD GlobalLoop Capital\n\n\nDigital financial services provider being spun out of AMTD.\n\n\nMiromatrix Medical (MIRO)Eden Prairie, MN\n$32M$162M\n$7 - $94,000,000\nCraig-Hallum\n\n\nDeveloping novel bioengineering technology for organ transplants.\n\n\nUnicycive Therapeutics (UNCY)Los Altos, CA\n$25M$116M\n$8.50 - $10.502,635,000\nRoth Cap.\n\n\nEarly-stage biotech developing in-licensed therapies for kidney disease.\n\n\n\nStreet research is expected for seven companies, and lock-up periods will be expiring for up to two companies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":807477898,"gmtCreate":1628054319814,"gmtModify":1703500369870,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Inari has good prospect! At 18x is a good bargain","listText":"Inari has good prospect! At 18x is a good bargain","text":"Inari has good prospect! At 18x is a good bargain","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/807477898","repostId":"1124757232","repostType":4,"repost":{"id":"1124757232","pubTimestamp":1628045612,"share":"https://ttm.financial/m/news/1124757232?lang=&edition=fundamental","pubTime":"2021-08-04 10:53","market":"us","language":"en","title":"3 COVID Stocks That Could Soar Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1124757232","media":"The Motley Fool","summary":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfi","content":"<p><b><i>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.</i></b></p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Pfizer might surprise to the upside.</li>\n <li>Inari Medical is growing like gangbusters.</li>\n <li>Novavax's vaccine might be an important booster shot as the COVID-19 virus mutates.</li>\n</ul>\n<p>COVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?</p>\n<p>A panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of&nbsp;<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/NARI\">Inari Medical, Inc.</a></b>, and&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f3ed6a343e35e121aafbaa2b30134955\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<h3><b>Pfizer: More room to run</b></h3>\n<p><b>George Budwell</b>&nbsp;<b>(Pfizer):</b>&nbsp;American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;-- losing steam from a sales perspective starting in 2022.</p>\n<p>Because of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.</p>\n<p>There are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company&nbsp;announced&nbsp;that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.</p>\n<p>Although the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.</p>\n<p>The big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.</p>\n<p>Where is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a&nbsp;dividend-paying&nbsp;big pharma stock.</p>\n<h3><b>Inari Medical: Skyrocketing Sales</b></h3>\n<p><b>Patrick Bafuma</b>&nbsp;<b>(Inari Medical):</b>&nbsp;If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to&nbsp;<i>The New York Times</i>&nbsp;-- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.</p>\n<p>This seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021,&nbsp;up 130% from the same quarter last year&nbsp;and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according to<i>The Times</i>, Inari is likely to see an uptick in eligible cases.</p>\n<p>Not to mention the company's results thus far for blood clots in the lung are spectacular:</p>\n<ul>\n <li>With the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.</li>\n <li>There's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.</li>\n <li>Major adverse events within 48 hours occur at only a 1.3% rate.</li>\n <li>No ICU stays are required after the procedure.</li>\n</ul>\n<p>Add it all up, and Inari's retrieval device seems like an obvious choice.</p>\n<p>The company grew first-quarter revenue at 113% year over year, and&nbsp;18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.</p>\n<p>Inari has&nbsp;less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.</p>\n<h3><b>Novavax: How high can it go?</b></h3>\n<p><b>Taylor Carmichael</b>&nbsp;<b>(Novavax):</b>&nbsp;The vaccine&nbsp;biotech&nbsp;Novavax had an amazing 2020, with its share price running up&nbsp;2,700%&nbsp;on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0e7829d99a76c48579ba01c6e55fe14f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>NVAX DATA BY YCHARTS.</span></p>\n<p>Positive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.</p>\n<p>Despite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.</p>\n<p>In the U.S., the Novavax vaccine might primarily be used as a&nbsp;booster shot&nbsp;for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told&nbsp;<i>The New York Times</i>.</p>\n<p>Down the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Could Soar Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Could Soar Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 10:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/><strong>The Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NARI":"Inari Medical, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/03/3-covid-stocks-that-will-soar-higher/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124757232","content_text":"Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.\nKey Points\n\nPfizer might surprise to the upside.\nInari Medical is growing like gangbusters.\nNovavax's vaccine might be an important booster shot as the COVID-19 virus mutates.\n\nCOVID-19 and the international lockdown crashed the world economy in 2020. Many people have already been vaccinated and are looking forward to normalization. But COVID is mutating, and the new delta variant might toss a wrench into the world's reopening. How might investors protect themselves?\nA panel of Motley Fool contributors offers three ideas for healthcare stocks that will zoom higher in 2021, even if COVID takes a turn for the worse. Read more to see why you might want to buy shares of Pfizer, Inari Medical, Inc., and Novavax.\nIMAGE SOURCE: GETTY IMAGES.\nPfizer: More room to run\nGeorge Budwell (Pfizer): American pharma titan Pfizer might not sound like a sexy pick among the present cohort of COVID vaccine players. Wall Street's current consensus has Comirnaty, the drugmaker's vaccine -- produced in partnership with BioNTech SE -- losing steam from a sales perspective starting in 2022.\nBecause of the delta variant, however, Comirnaty's commercial life could turn out to be much longer than originally expected. And while the emergence of the highly transmissible variant is obviously terrible news for society at large, Pfizer and its shareholders are probably going to benefit from this unfortunate development.\nThere are two clear reasons to think that Pfizer's stock could move higher on the delta issue. First and foremost, the company announced that an Emergency Use Authorization submission for a booster third shot might happen as soon as this month. Second, Pfizer plans to start clinical trials for a delta-specific version of the vaccine this month.\nAlthough the Food and Drug Administration and the Centers for Disease Control and Prevention have both recently downplayed the need for booster shots, Pfizer has already put forth a compelling case for a third jab in response to the rampant spread of the delta variant and the waning efficacy of Comirnaty 6 to 12 months following full vaccination.\nThe big picture for investors is that Pfizer's 2022 revenue might jump by as much as 9.7% compared to 2021 -- that is, if a booster shot is indeed approved and the company also successfully develops a delta-specific vaccine. By contrast, Wall Street currently has the drugmaker's top line falling by 14.8% next year relative to 2021.\nWhere is Pfizer's stock possibly headed? If all the pieces fall into place on the vaccine front, shares ought to command a $50 handle, from a conservative standpoint. That's roughly a 17% upswing from where the drugmaker's shares presently stand, and that's not even accounting for the company's attractive 3.64% dividend yield at current levels. Put simply, Pfizer's stock would only be trading at approximately 3.5 times 2022 sales if this scenario pans out, which is a rather modest valuation for a dividend-paying big pharma stock.\nInari Medical: Skyrocketing Sales\nPatrick Bafuma (Inari Medical): If you are looking for a stock with staying power after tailwinds from the pandemic subside, look to Inari Medical. There were 108,000 new COVID cases on July 27, 2021 -- the most since February 5, 2021, according to The New York Times -- and that number was up over eight times the seven-day average at the start of July. To make things even worse, COVID not only causes difficulty breathing but also more than triples a patient's risk of disabling and potentially life-threatening blood clots. And we're still not sure if being vaccinated fully mitigates the risk of blood clots when a patient has an asymptomatic or a mild COVID infection.\nThis seems like a good setup for a commercial-stage med-tech company that has developed minimally invasive products designed to remove large blood clots without the need for powerful clot-busting drugs. Through the use of its ClotTriever and FlowTriever devices, Inari has treated over 25,000 patients so far. Clinicians performed approximately 5,500 procedures with the company's devices in the first quarter of 2021, up 130% from the same quarter last year and about 20% higher than the fourth quarter of 2020. With about 12% of admitted COVID patients developing blood clots, and about 35,000 COVID hospitalizations in the U.S. (and rising) as of July 27, according toThe Times, Inari is likely to see an uptick in eligible cases.\nNot to mention the company's results thus far for blood clots in the lung are spectacular:\n\nWith the historic 30-day mortality rate of intermediate and high-risk blood clots in the lungs at 9.7%, Inari's 0.4% 30-day mortality rate is impressive.\nThere's a decreased 30-day readmission rate of 6.7% versus 24.4% with the usual care.\nMajor adverse events within 48 hours occur at only a 1.3% rate.\nNo ICU stays are required after the procedure.\n\nAdd it all up, and Inari's retrieval device seems like an obvious choice.\nThe company grew first-quarter revenue at 113% year over year, and 18% sequentially, and had gross margins of 91.9% for the first quarter of 2021. So Inari's price-to-sales ratio of 18 makes it a growth stock on sale.\nInari has less than 5% penetrationin the $3.8 billion U.S. market, and there's also lots of room to grow in Europe, where it launched earlier this year. That means there are plenty of opportunities for this $4.5-billion market cap company. While COVID has affected many elective and semi-elective procedures, it has clearly not slowed Inari, and it could even accelerate its uptake.\nNovavax: How high can it go?\nTaylor Carmichael (Novavax): The vaccine biotech Novavax had an amazing 2020, with its share price running up 2,700% on optimism for its COVID vaccine. While the company has yet to file for an Emergency Use Authorization, it expects to do so in this quarter. So far in 2021, the stock is up 60%.\nNVAX DATA BY YCHARTS.\nPositive phase 3 data for the COVID-19 vaccine sent the stock soaring early in the year, but the share price has come back down to earth as the company has suffered delays getting its vaccine to market. First there was a shortage of raw materials necessary to make the vaccine. Now the company has to prove that its various contract manufacturing facilities will keep the vaccine quality consistent across all the sites.\nDespite these delays, long-term investors have reasons to be bullish. Manufacturing is scaling up, with production rates expected to hit 100 million doses a month by the end of the third quarter, and 150 million doses a month by December. While many people in the U.S. have already been vaccinated, the opportunity in the rest of the world is sizable. Novavax has pre-sold 1.1 billion doses to COVAX (an international vaccine consortium), and has contracted to supply hundreds of millions of doses around the world.\nIn the U.S., the Novavax vaccine might primarily be used as a booster shot for people who have already been vaccinated. \"They may be really the right ones for boosters,\" Dr. Luciana Borio, the acting chief scientist at the F.D.A. from 2015 to 2017, told The New York Times.\nDown the road, Novavax plans on combining its COVID vaccine with its flu vaccine, making aone-shot regimen. While COVID does not mutate as quickly as the flu, we've seen several mutating strains over the last year. It's likely that we will need to vaccinate more than once in the years ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":481,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164303913,"gmtCreate":1624169362532,"gmtModify":1703830070407,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Nice sharing","listText":"Nice sharing","text":"Nice sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/164303913","repostId":"1199331995","repostType":4,"repost":{"id":"1199331995","pubTimestamp":1624065374,"share":"https://ttm.financial/m/news/1199331995?lang=&edition=fundamental","pubTime":"2021-06-19 09:16","market":"us","language":"en","title":"U.S. IPO Week Ahead: Billion-Dollar Deals Come To Market In A 12 IPO Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1199331995","media":"Renaissance","summary":"12 IPOs are scheduled to raise $5.6 billion in the week ahead led by two billion-dollar deals.Chinese freight platform Full Truck Alliance plans to raise $1.5 billion at a $19.7 billion market cap. The company’s platform connects shippers with truckers to facilitate shipments across distance ranges, cargo weights, and types. Full Truck states that it is the world's largest digital freight platform by gross transaction value , facilitating 22+ million fulfilled orders with GTV of nearly $8 billio","content":"<p>12 IPOs are scheduled to raise $5.6 billion in the week ahead led by two billion-dollar deals.</p>\n<p>Chinese freight platform&nbsp;<b>Full Truck Alliance</b>(YMM) plans to raise $1.5 billion at a $19.7 billion market cap. The company’s platform connects shippers with truckers to facilitate shipments across distance ranges, cargo weights, and types. Full Truck states that it is the world's largest digital freight platform by gross transaction value (GTV), facilitating 22+ million fulfilled orders with GTV of nearly $8 billion in the 1Q21.</p>\n<p>Healthcare manager&nbsp;<b>Bright Health Group</b>(BHG) plans to raise $1.3 billion at a $15.4 billion market cap. Bright Health seeks to employ a more consumer-centric approach to healthcare to improve consumer experiences. Through a multi-pronged organic and inorganic growth strategy, the company’s core business has grown to serve roughly 623,000 patients in 14 states since its founding.</p>\n<p>Data infrastructure provider&nbsp;<b>Confluent</b>(CFLT) plans to raise $713 million at a $10.0 billion market cap. Confluent data infrastructure offering is designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. The company had more than 2,500 customers as of March 2021, with a dollar-based net retention rate of 117%.</p>\n<p>Car wash brand&nbsp;<b>Mister Car Wash</b>(MCW) plans to raise $600 million at a $5.3 billion market cap. Profitable with solid cash flow, Mister Car Wash is the largest national car wash brand in the US, with 344 locations in 21 states. The company offers a monthly subscription program called Unlimited Wash Club which had 1.4 million members as of 3/31/21, representing nearly two-thirds of total wash sales.</p>\n<p>Digital physicians network&nbsp;<b>Doximity</b>(DOCS) plans to raise $501 million at a $4.5 billion market cap. Doximity claims that it is the leading digital platform for US medical professionals, allowing collaboration with colleagues and secure coordination of patient care, among other features. Fast growing and profitable, the company had over 1.8 million members as of 3/31/21, representing more than 80% of physicians across the country.</p>\n<p>Customer experience software provider&nbsp;<b>Sprinklr</b>(CXM) plans to raise $361 million at a $5.5 billion market cap. Sprinklr provides a software platform that helps enterprises create a persistent, unified view of each customer at scale. The company has attracted more than 1,000 customers, including over 50% of the Fortune 100. Sprinklr has improved its gross margins, though cash flow swung negative in 1Q FY22.</p>\n<p>HR platform provider&nbsp;<b>First Advantage</b>(FA) plans to raise $298 million at a $2.1 billion market cap. First Advantage provides technology solutions for screening, verifications, safety, and compliance related to human capital. Profitable with positive cash flow, the company derives most of its revenues from pre-onboarding screening, performing over 75 million screens on behalf of more than 30,000 customers in 2020.</p>\n<p>Chinese social networking platform&nbsp;<b>Soulgate</b>(SSR) plans to raise $185 million at a $1.8 billion market cap. The company’s app Soul is a virtual social network created to address the drawbacks of current social media platforms. In March 2021, the company averaged 9.1 million DAUs, a 94% increase over the prior year period.</p>\n<p>Digital financial services provider&nbsp;<b>AMTD Digital</b>(HKD) plans to raise $120 million at a $1.4 billion market cap. AMTD Digital states that it is the \"fusion reactor\" at the core of the AMTD SpiderNet ecosystem, operating a comprehensive digital solutions platform in Asia. Profitable with explosive growth, the company primarily generates revenue from fees and commissions in two lines of business.</p>\n<p>Organ bioengineering company&nbsp;<b>Miromatrix Medical</b>(MIRO) plans to raise $32 million at a $162 million market cap. Miromatrix is developing a novel technology for bioengineering fully transplantable human organs, initially focused on livers and kidneys. The company has demonstrated functional vasculature and important organ function in preclinical studies, and hopes to initiate a Phase 1 trial in late 2022 with its External Liver Assist Product.</p>\n<p>Kidney disease biotech&nbsp;<b>Unicycive Therapeutics</b>(UNCY) plans to raise $25 million at a $116 million market cap. The company’s candidates include Renazorb, which was in-licensed from Spectrum Pharmaceuticals, and UNI 494, which was in-licensed from Sphaera Pharmaceuticals. Unicycive began conducting preclinical trials on UNI 494 in 2020.</p>\n<p>Antibiotic biotech&nbsp;<b>Acurx Pharmaceuticals</b>(ACXP) plans to raise $15 million at a $62 million market cap. The company is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the WHO, CDC, and USDA. Its lead candidate recently completed a Phase 2a trial in patients with C. difficile infections, and is expected to begin a Phase 2b trial this year.</p>\n<table>\n <tbody>\n  <tr>\n   <th>U.S. IPO Calendar</th>\n  </tr>\n  <tr>\n   <th>Issuer Business</th>\n   <th>Deal Size Market Cap</th>\n   <th>Price Range Shares Filed</th>\n   <th>Top Bookrunners</th>\n  </tr>\n  <tr>\n   <td><p>Full Truck Alliance (YMM)</p><p>Guiyang, China</p></td>\n   <td>$1,485M$19,723M</td>\n   <td>$17 - $1982,500,000</td>\n   <td>Morgan StanleyCICC</td>\n  </tr>\n  <tr>\n   <td>Digital freight platform that connects shippers and truckers in China.</td>\n  </tr>\n  <tr>\n   <td><p>First Advantage (FA)</p><p>Atlanta, GA</p></td>\n   <td>$298M$2,097M</td>\n   <td>$13 - $1521,250,000</td>\n   <td>BarclaysBofA</td>\n  </tr>\n  <tr>\n   <td>Provides background checks and other services to corporate customers.</td>\n  </tr>\n  <tr>\n   <td><p>Sprinklr (CXM)</p><p>New York, NY</p></td>\n   <td>$361M$5,541M</td>\n   <td>$18 - $2019,000,000</td>\n   <td>Morgan StanleyJP Morgan</td>\n  </tr>\n  <tr>\n   <td>Provides customer experience management software for enterprises.</td>\n  </tr>\n  <tr>\n   <td><p>Bright Health Group (BHG)</p><p>Minneapolis, MN</p></td>\n   <td>$1,290M$15,385M</td>\n   <td>$20 - $2360,000,000</td>\n   <td>JP MorganGoldman</td>\n  </tr>\n  <tr>\n   <td>Provides health insurance and other healthcare services.</td>\n  </tr>\n  <tr>\n   <td><p>Confluent (CFLT)</p><p>Mountain View, CA</p></td>\n   <td>$713M$10,033M</td>\n   <td>$29 - $3323,000,000</td>\n   <td>Morgan StanleyJP Morgan</td>\n  </tr>\n  <tr>\n   <td>Provides an enterprise platform that collects and processes real-time data streams.</td>\n  </tr>\n  <tr>\n   <td><p>Doximity (DOCS)</p><p>San Francisco, CA</p></td>\n   <td>$501M$4,549M</td>\n   <td>$20 - $2323,300,000</td>\n   <td>Morgan StanleyGoldman</td>\n  </tr>\n  <tr>\n   <td>Professional network for physicians with telehealth and scheduling tools.</td>\n  </tr>\n  <tr>\n   <td><p>Soulgate (SSR)</p><p>Shanghai, China</p></td>\n   <td>$185M$1,824M</td>\n   <td>$13 - $1513,200,000</td>\n   <td>Morgan StanleyJefferies</td>\n  </tr>\n  <tr>\n   <td>Provides the gamified social networking app Soul in China.</td>\n  </tr>\n  <tr>\n   <td><p>Acurx Pharmaceuticals (ACXP)</p><p>Staten Island, NY</p></td>\n   <td>$15M$62M</td>\n   <td>$5 - $72,500,000</td>\n   <td>Alexander CapitalNetwork 1</td>\n  </tr>\n  <tr>\n   <td>Phase 2 biotech developing antibiotics for antibiotic-resistant pathogens.</td>\n  </tr>\n  <tr>\n   <td><p>Mister Car Wash (MCW)</p><p>Tucson, AZ</p></td>\n   <td>$600M$5,256M</td>\n   <td>$15 - $1737,500,000</td>\n   <td>BofAMorgan Stanley</td>\n  </tr>\n  <tr>\n   <td>Leading national car wash brand with 344 locations across the US.</td>\n  </tr>\n  <tr>\n   <td><p>AMTD Digital (HKD)</p><p>Hong Kong, China</p></td>\n   <td>$120M$1,388M</td>\n   <td>$6.80 - $8.2016,000,000</td>\n   <td>AMTD GlobalLoop Capital</td>\n  </tr>\n  <tr>\n   <td>Digital financial services provider being spun out of AMTD.</td>\n  </tr>\n  <tr>\n   <td><p>Miromatrix Medical (MIRO)</p><p>Eden Prairie, MN</p></td>\n   <td>$32M$162M</td>\n   <td>$7 - $94,000,000</td>\n   <td>Craig-Hallum</td>\n  </tr>\n  <tr>\n   <td>Developing novel bioengineering technology for organ transplants.</td>\n  </tr>\n  <tr>\n   <td><p>Unicycive Therapeutics (UNCY)</p><p>Los Altos, CA</p></td>\n   <td>$25M$116M</td>\n   <td>$8.50 - $10.502,635,000</td>\n   <td>Roth Cap.</td>\n  </tr>\n  <tr>\n   <td>Early-stage biotech developing in-licensed therapies for kidney disease.</td>\n  </tr>\n </tbody>\n</table>\n<p>Street research is expected for seven companies, and lock-up periods will be expiring for up to two companies.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. IPO Week Ahead: Billion-Dollar Deals Come To Market In A 12 IPO Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. IPO Week Ahead: Billion-Dollar Deals Come To Market In A 12 IPO Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-19 09:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4435613-us-ipo-week-ahead-billion-dollar-deals-come-to-market-in-a-12-ipo-week><strong>Renaissance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12 IPOs are scheduled to raise $5.6 billion in the week ahead led by two billion-dollar deals.\nChinese freight platform Full Truck Alliance(YMM) plans to raise $1.5 billion at a $19.7 billion market ...</p>\n\n<a href=\"https://seekingalpha.com/article/4435613-us-ipo-week-ahead-billion-dollar-deals-come-to-market-in-a-12-ipo-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"YMM":"满帮","DOCS":"Doximity, Inc.","MCW":"Mister Car Wash, Inc.","FA":"First Advantage Corp.","CXM":"Sprinklr, Inc.","CFLT":"Confluent, Inc."},"source_url":"https://seekingalpha.com/article/4435613-us-ipo-week-ahead-billion-dollar-deals-come-to-market-in-a-12-ipo-week","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1199331995","content_text":"12 IPOs are scheduled to raise $5.6 billion in the week ahead led by two billion-dollar deals.\nChinese freight platform Full Truck Alliance(YMM) plans to raise $1.5 billion at a $19.7 billion market cap. The company’s platform connects shippers with truckers to facilitate shipments across distance ranges, cargo weights, and types. Full Truck states that it is the world's largest digital freight platform by gross transaction value (GTV), facilitating 22+ million fulfilled orders with GTV of nearly $8 billion in the 1Q21.\nHealthcare manager Bright Health Group(BHG) plans to raise $1.3 billion at a $15.4 billion market cap. Bright Health seeks to employ a more consumer-centric approach to healthcare to improve consumer experiences. Through a multi-pronged organic and inorganic growth strategy, the company’s core business has grown to serve roughly 623,000 patients in 14 states since its founding.\nData infrastructure provider Confluent(CFLT) plans to raise $713 million at a $10.0 billion market cap. Confluent data infrastructure offering is designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. The company had more than 2,500 customers as of March 2021, with a dollar-based net retention rate of 117%.\nCar wash brand Mister Car Wash(MCW) plans to raise $600 million at a $5.3 billion market cap. Profitable with solid cash flow, Mister Car Wash is the largest national car wash brand in the US, with 344 locations in 21 states. The company offers a monthly subscription program called Unlimited Wash Club which had 1.4 million members as of 3/31/21, representing nearly two-thirds of total wash sales.\nDigital physicians network Doximity(DOCS) plans to raise $501 million at a $4.5 billion market cap. Doximity claims that it is the leading digital platform for US medical professionals, allowing collaboration with colleagues and secure coordination of patient care, among other features. Fast growing and profitable, the company had over 1.8 million members as of 3/31/21, representing more than 80% of physicians across the country.\nCustomer experience software provider Sprinklr(CXM) plans to raise $361 million at a $5.5 billion market cap. Sprinklr provides a software platform that helps enterprises create a persistent, unified view of each customer at scale. The company has attracted more than 1,000 customers, including over 50% of the Fortune 100. Sprinklr has improved its gross margins, though cash flow swung negative in 1Q FY22.\nHR platform provider First Advantage(FA) plans to raise $298 million at a $2.1 billion market cap. First Advantage provides technology solutions for screening, verifications, safety, and compliance related to human capital. Profitable with positive cash flow, the company derives most of its revenues from pre-onboarding screening, performing over 75 million screens on behalf of more than 30,000 customers in 2020.\nChinese social networking platform Soulgate(SSR) plans to raise $185 million at a $1.8 billion market cap. The company’s app Soul is a virtual social network created to address the drawbacks of current social media platforms. In March 2021, the company averaged 9.1 million DAUs, a 94% increase over the prior year period.\nDigital financial services provider AMTD Digital(HKD) plans to raise $120 million at a $1.4 billion market cap. AMTD Digital states that it is the \"fusion reactor\" at the core of the AMTD SpiderNet ecosystem, operating a comprehensive digital solutions platform in Asia. Profitable with explosive growth, the company primarily generates revenue from fees and commissions in two lines of business.\nOrgan bioengineering company Miromatrix Medical(MIRO) plans to raise $32 million at a $162 million market cap. Miromatrix is developing a novel technology for bioengineering fully transplantable human organs, initially focused on livers and kidneys. The company has demonstrated functional vasculature and important organ function in preclinical studies, and hopes to initiate a Phase 1 trial in late 2022 with its External Liver Assist Product.\nKidney disease biotech Unicycive Therapeutics(UNCY) plans to raise $25 million at a $116 million market cap. The company’s candidates include Renazorb, which was in-licensed from Spectrum Pharmaceuticals, and UNI 494, which was in-licensed from Sphaera Pharmaceuticals. Unicycive began conducting preclinical trials on UNI 494 in 2020.\nAntibiotic biotech Acurx Pharmaceuticals(ACXP) plans to raise $15 million at a $62 million market cap. The company is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the WHO, CDC, and USDA. Its lead candidate recently completed a Phase 2a trial in patients with C. difficile infections, and is expected to begin a Phase 2b trial this year.\n\n\n\nU.S. IPO Calendar\n\n\nIssuer Business\nDeal Size Market Cap\nPrice Range Shares Filed\nTop Bookrunners\n\n\nFull Truck Alliance (YMM)Guiyang, China\n$1,485M$19,723M\n$17 - $1982,500,000\nMorgan StanleyCICC\n\n\nDigital freight platform that connects shippers and truckers in China.\n\n\nFirst Advantage (FA)Atlanta, GA\n$298M$2,097M\n$13 - $1521,250,000\nBarclaysBofA\n\n\nProvides background checks and other services to corporate customers.\n\n\nSprinklr (CXM)New York, NY\n$361M$5,541M\n$18 - $2019,000,000\nMorgan StanleyJP Morgan\n\n\nProvides customer experience management software for enterprises.\n\n\nBright Health Group (BHG)Minneapolis, MN\n$1,290M$15,385M\n$20 - $2360,000,000\nJP MorganGoldman\n\n\nProvides health insurance and other healthcare services.\n\n\nConfluent (CFLT)Mountain View, CA\n$713M$10,033M\n$29 - $3323,000,000\nMorgan StanleyJP Morgan\n\n\nProvides an enterprise platform that collects and processes real-time data streams.\n\n\nDoximity (DOCS)San Francisco, CA\n$501M$4,549M\n$20 - $2323,300,000\nMorgan StanleyGoldman\n\n\nProfessional network for physicians with telehealth and scheduling tools.\n\n\nSoulgate (SSR)Shanghai, China\n$185M$1,824M\n$13 - $1513,200,000\nMorgan StanleyJefferies\n\n\nProvides the gamified social networking app Soul in China.\n\n\nAcurx Pharmaceuticals (ACXP)Staten Island, NY\n$15M$62M\n$5 - $72,500,000\nAlexander CapitalNetwork 1\n\n\nPhase 2 biotech developing antibiotics for antibiotic-resistant pathogens.\n\n\nMister Car Wash (MCW)Tucson, AZ\n$600M$5,256M\n$15 - $1737,500,000\nBofAMorgan Stanley\n\n\nLeading national car wash brand with 344 locations across the US.\n\n\nAMTD Digital (HKD)Hong Kong, China\n$120M$1,388M\n$6.80 - $8.2016,000,000\nAMTD GlobalLoop Capital\n\n\nDigital financial services provider being spun out of AMTD.\n\n\nMiromatrix Medical (MIRO)Eden Prairie, MN\n$32M$162M\n$7 - $94,000,000\nCraig-Hallum\n\n\nDeveloping novel bioengineering technology for organ transplants.\n\n\nUnicycive Therapeutics (UNCY)Los Altos, CA\n$25M$116M\n$8.50 - $10.502,635,000\nRoth Cap.\n\n\nEarly-stage biotech developing in-licensed therapies for kidney disease.\n\n\n\nStreet research is expected for seven companies, and lock-up periods will be expiring for up to two companies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178447118,"gmtCreate":1626834329134,"gmtModify":1703766088604,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"What happen to Blue zmoon? Turning to Red Moon now","listText":"What happen to Blue zmoon? Turning to Red Moon now","text":"What happen to Blue zmoon? Turning to Red Moon now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/178447118","repostId":"2153137486","repostType":4,"isVote":1,"tweetType":1,"viewCount":253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167784825,"gmtCreate":1624285036867,"gmtModify":1703832491861,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Will the drop ripple to Lithium and battery stock as well?","listText":"Will the drop ripple to Lithium and battery stock as well?","text":"Will the drop ripple to Lithium and battery stock as well?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/167784825","repostId":"1136791321","repostType":4,"repost":{"id":"1136791321","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624282996,"share":"https://ttm.financial/m/news/1136791321?lang=&edition=fundamental","pubTime":"2021-06-21 21:43","market":"us","language":"en","title":"EV stocks fell in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1136791321","media":"Tiger Newspress","summary":"(June 21) EV stocks fell in morning trading.","content":"<p>(June 21)&nbsp;EV stocks fell in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e7e7cf675e122ca02f2d220cde025a88\" tg-width=\"310\" tg-height=\"239\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-21 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 21)&nbsp;EV stocks fell in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/e7e7cf675e122ca02f2d220cde025a88\" tg-width=\"310\" tg-height=\"239\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","NIO":"蔚来","TSLA":"特斯拉","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136791321","content_text":"(June 21) EV stocks fell in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807702702,"gmtCreate":1628054881506,"gmtModify":1703500380345,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Will the booster jab (3rd jab vaccination)&nbsp;boost the share ptocebof PFE ?","listText":"Will the booster jab (3rd jab vaccination)&nbsp;boost the share ptocebof PFE ?","text":"Will the booster jab (3rd jab vaccination) boost the share ptocebof PFE ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807702702","repostId":"1156524625","repostType":4,"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807700409,"gmtCreate":1628054431501,"gmtModify":1703500371024,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Toyota! My trusted car","listText":"Toyota! My trusted car","text":"Toyota! My trusted car","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807700409","repostId":"1136976094","repostType":4,"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178473966,"gmtCreate":1626834447955,"gmtModify":1703766092504,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"What about Nio; Xpeng Lucid etc etc ?","listText":"What about Nio; Xpeng Lucid etc etc ?","text":"What about Nio; Xpeng Lucid etc etc ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178473966","repostId":"1110113604","repostType":4,"isVote":1,"tweetType":1,"viewCount":442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165180151,"gmtCreate":1624105769673,"gmtModify":1703828891106,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Up u up","listText":"Up u up","text":"Up u up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/165180151","repostId":"1148576248","repostType":4,"repost":{"id":"1148576248","pubTimestamp":1623979883,"share":"https://ttm.financial/m/news/1148576248?lang=&edition=fundamental","pubTime":"2021-06-18 09:31","market":"us","language":"en","title":"NIO Is Winning","url":"https://stock-news.laohu8.com/highlight/detail?id=1148576248","media":"seekingalpha","summary":"NIO is #1 in China's electric SUV market for good reason.The company's success is driven by its brilliant innovations and marketing strategy.NIO is growing faster than Tesla, and yet, it is trading at a discount.NIO Inc.  stands out for its strong market position- #1 market share in electric SUV in China- and innovation in the rapidly growing and highly competitive electric vehicle industry. This article will discuss why NIO is winning against some stiff competition, including against Tesla .In ","content":"<p><b>Summary</b></p>\n<ul>\n <li>NIO is #1 in China's electric SUV market for good reason.</li>\n <li>The company's success is driven by its brilliant innovations and marketing strategy.</li>\n <li>NIO is growing faster than Tesla, and yet, it is trading at a discount.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/790fae23b830463fec748d2deb2ce336\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>PonyWang/E+ via Getty Images</span></p>\n<p>NIO Inc. (NYSE:NIO) stands out for its strong market position- #1 market share in electric SUV in China- and innovation in the rapidly growing and highly competitive electric vehicle industry. This article will discuss why NIO is winning against some stiff competition, including against Tesla (TSLA).</p>\n<p>In addition, we will discuss NIO's business, financials, trading, valuation, and risks so readers could reach their own informed decision.</p>\n<p><b>Business: Why NIO Wins</b></p>\n<p>NIO positions itself in the premium SUV segment, focusing on smart EVs with a differentiated battery strategy.</p>\n<p>Delivered in March 2019, the company's first model, the ES8, is a luxury 7-seater SUV that is still the company's flagship product today. The ES8 is equipped with ADAS and AI system [NOMI] and is comparable to the BYD Song, Tesla Model X, the Audi Q7 45 e-Tron, etc.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/443e2773f70c00c6faac8ca063e978a5\" tg-width=\"640\" tg-height=\"387\" referrerpolicy=\"no-referrer\"><span>Source: Company</span></p>\n<p>Leveraging the installed base and customer goodwill due to the highly successful ES8, NIO successfully launched the ES6 and EC6.Recently, the company launched the ET7, its first sedan.</p>\n<p>Today, NIO is the top-selling brand in China's all-electric SUV market in April with a 23% market share, higher than Tesla's 17%, WM Motor and XPeng Motors'(NYSE:XPEV)7%, according to China Automotive Technology and Research Center data.</p>\n<p>One of the biggest competitive differentiators is NIO'sbattery strategy, which all but eliminates range anxiety, one of the biggest barriers to mass EV adoption. Not only could NIO cars be charged at any charging station for EVs, but the company also built hundreds of battery swapping stations in key cities in China, with plans to expanding to Europe.</p>\n<p>NIO's battery swapping strategy also gives the company the ability to offer a battery-as-a-service [BaaS] solution, which reduces the upfrontcostof purchasing an NIO vehicle by ~$11,000. Since cost is another major barrier to mass EV adoption, NIO's battery strategy appears brilliant as it solves both the range and cost problems.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5b25fbb85bffd39310cd27cbb2bde57a\" tg-width=\"640\" tg-height=\"216\" referrerpolicy=\"no-referrer\"><span>Source: Company</span></p>\n<p>Another differentiator is the NIO brand, which management created brilliantly by introducing the EP9 in 2016. Six EP9s have been sold to NIO investors for 2.5 million pounds, creating an aura of exclusivity and quality around the brand. Next, NIO targeted the mass-market luxury SUV segment with the ES8, firmly establishing the company as a luxury car OEM.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ad41c960ce02f1e3f3e7575ac00beee0\" tg-width=\"640\" tg-height=\"350\" referrerpolicy=\"no-referrer\"><span>Source: Company</span></p>\n<p>Chinese companies must struggle against the common perception that they make low-quality products. This is the same perception issue that Japanese companies faced following their defeat after WW2. Japan solved this problem by moving up the value chain as their economy matured and creating high-quality brands such as Sony(NYSE:SONY). Today, Japan is known for its craftsmanship.</p>\n<p>China is following the same trajectory, and NIO is one of the emerging brands destroying the perception that \"made in China\" equates to poor quality. I strongly believe that investors who stubbornly hold on to that old perception will miss out on investing in some of the greatest brands the world will ever see.</p>\n<p>Buying an NIO car means much more than just getting a vehicle; it means getting into an exclusive club of services and convenience. Benefits include access to hundreds of swapping stations, lifetime free roadside rescue (including charge vans), lifetime free cellular connectivity, lifetime free warranty, and excellent customer service. This is a powerful selling point for NIO, differentiating it from Tesla, which hasrecentlydeveloped a poor reputation on the customer service front in China.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a73482aa0431694b760ab5c2d0aa6f53\" tg-width=\"640\" tg-height=\"211\" referrerpolicy=\"no-referrer\"><span>Source: Company</span></p>\n<p>The company is pushing the envelope even further with&nbsp;NIO House, a literal clubhouse for customers, and&nbsp;NIO Life, which includes NIO branded lifestyle products. NIO's effort to build a lifestyle around its cars seems to be&nbsp;working. This is good news for investors because the only way to escape the competitive battlefield of automobile OEM is to sell services and lifestyles to customers. This is why Ferrari's (RACE) operating margin is well over 20%, while Ford (F) and General Motors (GM) are in the single digits.</p>\n<p><b>Financials &amp; Valuation</b></p>\n<p>NIO is in hyper-growth mode. In 2020, the company generated $2.5 billion in revenue, up 126% y/y. In 2021, the company is expected to grow 117% y/y to $5.4 billion.</p>\n<p>The company is not yet profitable but is expected to be by 2022. Gross margin only turned positive in 2020 and is expected to be 19.3% in 2021. EBITDA is expected to be negative $258 million in 2021 and a positive $206 million in 2022. Free cash flow is expected to be negative $42 million in 2021 before turning to a positive $354 million in 2022.</p>\n<p>However, despite the cash burn expected in 2021, investors should feel at ease since the company exited&nbsp;2020&nbsp;with $5.9 billion of cash and cash equivalents. Including $600 million in short-term investments and subtracting ~$2.1 billion in debt and operating leases and the expected negative free cash flow in 2021, NIO should exit 2021 with over $4 billion in net cash and investments. That is plenty of buffers since NIO is expected to generate positive free cash flow in 2022.</p>\n<p>Since NIO is not yet profitable, we will look at the forward EV/Sales multiple as is typical for hyper-growth companies not yet generating a profit. The company went public in September 2018, trading at around 7 to 8 times EV/Sales, before bottoming out at around 0.7 times sales in May 2019. The market, however, caught the EV fever in April 2020 and sent NIO's valuation soaring to a peak of 14.6x by January 2021. After the growth sell-off we recently experienced, NIO is currently sitting at a much more reasonable 8 times forward sales. This is a significant discount to TSLA's 10.2 times forward EV/Sales despite growing twice as fast (TSLA is expected to grow revenues by 57% in 2021 compared to NIO's 117%).</p>\n<p><b>Risks</b></p>\n<p>There are many risks associated with owning NIO.</p>\n<p>Although its battery swapping strategy is highly differentiated and seems to be growing rapidly, the jury is still out on the ultimate market share of battery swapping or fast-charging infrastructure. If fast charging technology continues to advance significantly, it will likely erode a key advantage of battery swapping: speed.</p>\n<p>NIO's business model is innovative and new. Unfortunately, the flip side of that is that it is untested, and NIO remains unprofitable. For many investors, NIO will remain a \"show me\" story until the profitability of its business model improves.</p>\n<p>NIO's ability to expand globally may be limited by the rising geopolitical tension between China and the US, and to a lesser extent, with Japan and Europe. The geopolitical situation remains highly opaque and uncertain, and is a risk factor for all auto OEMs.</p>\n<p>Auto OEMs are currently facing a severe chip&nbsp;shortage. In addition, the chip density in automobiles is increasing, making the OEMs increasingly reliant on semiconductor suppliers and foundries.</p>\n<p>NIO's competitive advantages may not overcome the massive scale advantage of ICE OEMs and much bigger EV players like Tesla and China's BYD.</p>\n<p><b>Takeaway</b></p>\n<p>NIO's technical and business model innovations make it a highly differentiated company in the exciting and rapidly growing EV market. The company is winning, and its competitive moat is getting bigger as its ecosystem of vehicles and services grows. Relative to the industry leader, Tesla, NIO's stock price seems like a bargain given its faster growth rate and lower multiples.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NIO Is Winning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNIO Is Winning\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 09:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4435341-nio-is-winning><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nNIO is #1 in China's electric SUV market for good reason.\nThe company's success is driven by its brilliant innovations and marketing strategy.\nNIO is growing faster than Tesla, and yet, it is...</p>\n\n<a href=\"https://seekingalpha.com/article/4435341-nio-is-winning\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://seekingalpha.com/article/4435341-nio-is-winning","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148576248","content_text":"Summary\n\nNIO is #1 in China's electric SUV market for good reason.\nThe company's success is driven by its brilliant innovations and marketing strategy.\nNIO is growing faster than Tesla, and yet, it is trading at a discount.\n\nPonyWang/E+ via Getty Images\nNIO Inc. (NYSE:NIO) stands out for its strong market position- #1 market share in electric SUV in China- and innovation in the rapidly growing and highly competitive electric vehicle industry. This article will discuss why NIO is winning against some stiff competition, including against Tesla (TSLA).\nIn addition, we will discuss NIO's business, financials, trading, valuation, and risks so readers could reach their own informed decision.\nBusiness: Why NIO Wins\nNIO positions itself in the premium SUV segment, focusing on smart EVs with a differentiated battery strategy.\nDelivered in March 2019, the company's first model, the ES8, is a luxury 7-seater SUV that is still the company's flagship product today. The ES8 is equipped with ADAS and AI system [NOMI] and is comparable to the BYD Song, Tesla Model X, the Audi Q7 45 e-Tron, etc.\nSource: Company\nLeveraging the installed base and customer goodwill due to the highly successful ES8, NIO successfully launched the ES6 and EC6.Recently, the company launched the ET7, its first sedan.\nToday, NIO is the top-selling brand in China's all-electric SUV market in April with a 23% market share, higher than Tesla's 17%, WM Motor and XPeng Motors'(NYSE:XPEV)7%, according to China Automotive Technology and Research Center data.\nOne of the biggest competitive differentiators is NIO'sbattery strategy, which all but eliminates range anxiety, one of the biggest barriers to mass EV adoption. Not only could NIO cars be charged at any charging station for EVs, but the company also built hundreds of battery swapping stations in key cities in China, with plans to expanding to Europe.\nNIO's battery swapping strategy also gives the company the ability to offer a battery-as-a-service [BaaS] solution, which reduces the upfrontcostof purchasing an NIO vehicle by ~$11,000. Since cost is another major barrier to mass EV adoption, NIO's battery strategy appears brilliant as it solves both the range and cost problems.\nSource: Company\nAnother differentiator is the NIO brand, which management created brilliantly by introducing the EP9 in 2016. Six EP9s have been sold to NIO investors for 2.5 million pounds, creating an aura of exclusivity and quality around the brand. Next, NIO targeted the mass-market luxury SUV segment with the ES8, firmly establishing the company as a luxury car OEM.\nSource: Company\nChinese companies must struggle against the common perception that they make low-quality products. This is the same perception issue that Japanese companies faced following their defeat after WW2. Japan solved this problem by moving up the value chain as their economy matured and creating high-quality brands such as Sony(NYSE:SONY). Today, Japan is known for its craftsmanship.\nChina is following the same trajectory, and NIO is one of the emerging brands destroying the perception that \"made in China\" equates to poor quality. I strongly believe that investors who stubbornly hold on to that old perception will miss out on investing in some of the greatest brands the world will ever see.\nBuying an NIO car means much more than just getting a vehicle; it means getting into an exclusive club of services and convenience. Benefits include access to hundreds of swapping stations, lifetime free roadside rescue (including charge vans), lifetime free cellular connectivity, lifetime free warranty, and excellent customer service. This is a powerful selling point for NIO, differentiating it from Tesla, which hasrecentlydeveloped a poor reputation on the customer service front in China.\nSource: Company\nThe company is pushing the envelope even further with NIO House, a literal clubhouse for customers, and NIO Life, which includes NIO branded lifestyle products. NIO's effort to build a lifestyle around its cars seems to be working. This is good news for investors because the only way to escape the competitive battlefield of automobile OEM is to sell services and lifestyles to customers. This is why Ferrari's (RACE) operating margin is well over 20%, while Ford (F) and General Motors (GM) are in the single digits.\nFinancials & Valuation\nNIO is in hyper-growth mode. In 2020, the company generated $2.5 billion in revenue, up 126% y/y. In 2021, the company is expected to grow 117% y/y to $5.4 billion.\nThe company is not yet profitable but is expected to be by 2022. Gross margin only turned positive in 2020 and is expected to be 19.3% in 2021. EBITDA is expected to be negative $258 million in 2021 and a positive $206 million in 2022. Free cash flow is expected to be negative $42 million in 2021 before turning to a positive $354 million in 2022.\nHowever, despite the cash burn expected in 2021, investors should feel at ease since the company exited 2020 with $5.9 billion of cash and cash equivalents. Including $600 million in short-term investments and subtracting ~$2.1 billion in debt and operating leases and the expected negative free cash flow in 2021, NIO should exit 2021 with over $4 billion in net cash and investments. That is plenty of buffers since NIO is expected to generate positive free cash flow in 2022.\nSince NIO is not yet profitable, we will look at the forward EV/Sales multiple as is typical for hyper-growth companies not yet generating a profit. The company went public in September 2018, trading at around 7 to 8 times EV/Sales, before bottoming out at around 0.7 times sales in May 2019. The market, however, caught the EV fever in April 2020 and sent NIO's valuation soaring to a peak of 14.6x by January 2021. After the growth sell-off we recently experienced, NIO is currently sitting at a much more reasonable 8 times forward sales. This is a significant discount to TSLA's 10.2 times forward EV/Sales despite growing twice as fast (TSLA is expected to grow revenues by 57% in 2021 compared to NIO's 117%).\nRisks\nThere are many risks associated with owning NIO.\nAlthough its battery swapping strategy is highly differentiated and seems to be growing rapidly, the jury is still out on the ultimate market share of battery swapping or fast-charging infrastructure. If fast charging technology continues to advance significantly, it will likely erode a key advantage of battery swapping: speed.\nNIO's business model is innovative and new. Unfortunately, the flip side of that is that it is untested, and NIO remains unprofitable. For many investors, NIO will remain a \"show me\" story until the profitability of its business model improves.\nNIO's ability to expand globally may be limited by the rising geopolitical tension between China and the US, and to a lesser extent, with Japan and Europe. The geopolitical situation remains highly opaque and uncertain, and is a risk factor for all auto OEMs.\nAuto OEMs are currently facing a severe chip shortage. In addition, the chip density in automobiles is increasing, making the OEMs increasingly reliant on semiconductor suppliers and foundries.\nNIO's competitive advantages may not overcome the massive scale advantage of ICE OEMs and much bigger EV players like Tesla and China's BYD.\nTakeaway\nNIO's technical and business model innovations make it a highly differentiated company in the exciting and rapidly growing EV market. The company is winning, and its competitive moat is getting bigger as its ecosystem of vehicles and services grows. Relative to the industry leader, Tesla, NIO's stock price seems like a bargain given its faster growth rate and lower multiples.","news_type":1},"isVote":1,"tweetType":1,"viewCount":171,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9021630595,"gmtCreate":1653040550717,"gmtModify":1676535213137,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","listText":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","text":"Bla bka bla bla...but life must go on, hold steady and continue to have faith","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021630595","repostId":"2236030678","repostType":2,"repost":{"id":"2236030678","pubTimestamp":1653036810,"share":"https://ttm.financial/m/news/2236030678?lang=&edition=fundamental","pubTime":"2022-05-20 16:53","market":"us","language":"en","title":"Palantir: Complete Disaster","url":"https://stock-news.laohu8.com/highlight/detail?id=2236030678","media":"Seeking Alpha","summary":"So, Palantir Technologies Inc. (NYSE:PLTR) stock has been a total disaster for longs. Many retail \"b","content":"<html><head></head><body><p>So, <a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> (NYSE:PLTR) stock has been a total disaster for longs. Many retail &#34;bag-holders&#34; out there. And we would like to point out that we were wrong in our last column on the stock, despite making our members money. In our last column we predicted it would be emerging from the ashes and put out a profitable short-term trade recommendation in that piece. Winning.</p><p>However, <i>we were also wrong</i>, because we thought the bottom was put in after it reset back to trade just about at its direct public offering price. <i>We got that part wrong</i>.</p><p>While we get the win on the trade, we recognize that investors are getting creamed. Unfortunately this is a trader&#39;s market right now, and we have had a short bias the last few months, with selective long-term plays only in the most quality of names. We hate to see investors lose money, and we know it can be painful. The question is, what can we expect going forward. Is all hope lost here? We keep hearing that that technology stocks, especially those that are potential game-changing names, are on sale. But are they?</p><p>Names like Palantir are indeed often extremely expensive in the early stages. You really cannot value them on an earnings basis because there are no or very little earnings. Palantir also has a massive dilution problem, which means consistent positive EPS gets kicked further down the road. We think Palantir has a lot of potential, but this market is beyond unforgiving to those companies that do not make money or have sky high valuations. It does not matter at all how much promise they have; the stocks are all down and down massively. What can you do? We think there are three possible courses of action in the disaster that has been Palantir, all of which are correct.</p><p>The first option is the easiest, and perhaps a &#34;cop out&#34; for lack of a better term. But that option is to simply avoid the stock altogether in favor of deep value names offering some yield protection and are still managing to grow. We would not short down here at $7-$8, as the stock really has been pounded. The risk-reward is not favorable on a short after all of the action. So, you could do nothing and just watch it. If you own the stock, that would be a simple hold then. You could consider selling some upside calls on big bounces to lower cost basis if you choose.</p><p>The second course of action is in our wheelhouse. And that is to trade the name. Right now, we think that $7 level is a buy for gains to be sold at $8-$9, maybe $10. But this market environment is not going to get any better for innovative tech in the near-term. You could then consider some put options or mild shorts if the stock does enjoy a sizable bounce from the oversold conditions.</p><p>The third option is likely where a lot of readers are interested, and that is simply invest in the name, not obsess over the day-to-day tick in price. Add selectively to a well-rounded portfolio to improve cost basis, and put faith in management that it can deliver on growing the business profitably without diluting shareholders into oblivion. Right now this is a tall order for this company and management. While operationally the company is growing sufficiently, management has some credibility issues. What <a href=\"https://laohu8.com/S/AONE.U\">one</a> has to do is determine if what the company offers will solve enough headaches for customers that eventually the growing sales turn into sustained and growing profits.</p><p>For years, Palantir may lose money or breakeven. Of course, the theory goes that companies like this will lose money as they spend to attract customers and build their moat. They invest heavily in their growth while seeing revenues increase dramatically. And as we know, Palantir is seeing revenues grow tremendously.</p><p>So, what is our take? We think you wait for the next down day in the stock. It has enjoyed a sizable relief bounce from the lows, but we believe the stock will retest these lows as the economy continues to worsen, rates are going up, and markets struggle. We would be both traders and investors at $7. The risk could be that Palantir&#39;s growth fades and the company never really transforms the world. New competitors could emerge. Dilution could continue so long that positive EPS becomes out of reach without future buybacks. We hate to say it but frankly, it is not uncommon for stocks in seemingly innovative companies to wither away to sub $1 then eventually delist because the company failed to grow and deliver on its plans.</p><p>Although we were wrong in that bottom call, operationally we are seeing some positive signs. Internal metrics improve year-after-year for Palantir and we see no reason why the ongoing growth will not eventually lead to real profits, other than dilution. We admit and accept that so many great companies start out losing money. While the Russia/Ukraine conflict was a seemingly bullish development as it highlights a need to mine data for intelligence, some see a limited benefit for Palantir. For the long-term investor, we like a buy in this stock on weakness that sends the stock lower. While it will still be expensive, even for high growth tech, it will be much more reasonable compared to a few months ago. And it is not like the company is bleeding out and losing money hand over first. Palantir is breaking even and making some money some quarters.</p><h2>Palantir&#39;s Government and Commercial sectors showing growth</h2><p>In the just reported quarter, performance was strong on the top line and ahead of consensus estimates. Total revenue grew 31% year-over-year to $446 million, beating estimates by almost $3 million. However, its profitability was lower than expected by $0.02, and worse, guidance was less than consensus. That crushed the stock. But that said, both segments are doing well.</p><p>Palantir has two reporting segments: both the government and commercial segments. The commercial revenue stream continues to grow rapidly, while government results are likely to get a big boost following international strife. While the war in Ukraine may or may not lead to more business the company has invested in itself to grow sales. There are some concerns with backlog, but as we previously covered, Palantir has been hiring.</p><p>Palantir has expanded its sales team and they have been working to secure new orders. However, the Government revenues have slowed their growth somewhat. Deceleration of revenue growth is definitely a negative for a company like this that does not enjoy high earnings. They rose 16% from last year, and the company added a total of 40 net new customers in the quarter, which is very positive, 3 on the government side and 37 on the commercial side. We think it is important to note that the commercial space is doing well. The commercial revenue is expanding rapidly, increasing 132% in 2021, and here in Q1, it rose 54% year-over-year.</p><p>Palantir is seeing very positive momentum in its margins as well. Positive movement in margins is important in a software company as it really highlights strengths, or weaknesses, in the way it distributes its products. Palantir is delivering. Adjusted gross margin was 81%. Contribution margin was 57%. First quarter adjusted income from operations, excluding stock-based compensation and related employer payroll taxes was $117 million, representing an adjusted operating margin of 26%, ahead of management&#39;s prior guidance of 23%. This is positive.</p><h2>Palantir is slightly profitable, for now</h2><p>Despite the pull back now to single-digits, the stock is actually still expensive, like so many other growth tech names. The company lost $39 million in the quarter operationally, but adjusted income from operations was $117 million. The company is still free cash flow positive. Adjusted free cash flow was $30 million for the quarter. That said, the company was profitable at a $0.02 adjusted EPS bottom line figure, but this missed estimated by $0.02, so that is a negative, and another reason the stock is down.</p><p>We say the company is profitable for now for two reasons. First, there is a ton of stock based-compensation. This has been discussed in the past but we have to reiterate that we like that management has acknowledged that it is a problem. Still, it is ongoing, and every share that is issued waters down the ability to increase EPS. In short, shareholders could be diluted into losses. The second reason is that although there is growth internationally, as well as big gains in the U.S., we could see the government and companies slash spending if there is a recession. Each week, things seem to get worse in terms of how expensive things are, and corporate earnings reports continue to highlight the tremendous pressure inflation is putting on them. While Palantir&#39;s technology should help governments and businesses alike operate more efficiently, and therefore more profitably, we could see reduced spending on services like this.</p><h2>Still expensive</h2><p>On the valuation front, the stock is still pricey. Sure, looking at traditional price-to-earnings is futile, but if you did you would see a stock at like 50X. Very pricey. Perhaps the more appropriate measure is the price-to-sales ratio, but not only is this still very high, the market has basically said it is no longer willing to pay for sky high multiples. Keep that in mind. At 9X sales, the stock is much cheaper than it has ever been, but it is still not &#34;cheap&#34;. We would highlight that the PEG ratio is reasonable and we like the cash flow metrics.</p><h2>The outlook is murky</h2><p>The biggest concern right now is not valuation. It is not dilution. It is not the &#34;overall market.&#34; The largest issue is a slowdown in performance. The Q2 guidance was pretty weak. The company perhaps is underpromising to overdeliver, by management guided to a base case of $470 million in revenue. This was below consensus of $484 million. However in the release management noted that &#34;there is a wide range of potential upside to [the] guidance.&#34; The one positive factor to highlight is that Palantir continues to see 30% annual revenue growth through 2025.</p><h2>Take home</h2><p>The company operates with no debt and has nice positive free cash flow. They are poised to benefit from strong secular trends in big data and using analytics to improve operations. In the short-term, it is painful. Long-term, minus the dilution issues, there is a lot of promise here for future profits. The customer growth is impressive as is the revenue growth. While the stock has been a disaster, man analysts have price targets implying massive upside. We continue to see ongoing rapid growth in the U.S., but do caution that a big economic slowdown could hurt government and commercial spending. All things considered, on the next drawdown we would be buyers.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Complete Disaster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Complete Disaster\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 16:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4513287-palantir-complete-disaster><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, Palantir Technologies Inc. (NYSE:PLTR) stock has been a total disaster for longs. Many retail \"bag-holders\" out there. And we would like to point out that we were wrong in our last column on the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4513287-palantir-complete-disaster\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4513287-palantir-complete-disaster","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236030678","content_text":"So, Palantir Technologies Inc. (NYSE:PLTR) stock has been a total disaster for longs. Many retail \"bag-holders\" out there. And we would like to point out that we were wrong in our last column on the stock, despite making our members money. In our last column we predicted it would be emerging from the ashes and put out a profitable short-term trade recommendation in that piece. Winning.However, we were also wrong, because we thought the bottom was put in after it reset back to trade just about at its direct public offering price. We got that part wrong.While we get the win on the trade, we recognize that investors are getting creamed. Unfortunately this is a trader's market right now, and we have had a short bias the last few months, with selective long-term plays only in the most quality of names. We hate to see investors lose money, and we know it can be painful. The question is, what can we expect going forward. Is all hope lost here? We keep hearing that that technology stocks, especially those that are potential game-changing names, are on sale. But are they?Names like Palantir are indeed often extremely expensive in the early stages. You really cannot value them on an earnings basis because there are no or very little earnings. Palantir also has a massive dilution problem, which means consistent positive EPS gets kicked further down the road. We think Palantir has a lot of potential, but this market is beyond unforgiving to those companies that do not make money or have sky high valuations. It does not matter at all how much promise they have; the stocks are all down and down massively. What can you do? We think there are three possible courses of action in the disaster that has been Palantir, all of which are correct.The first option is the easiest, and perhaps a \"cop out\" for lack of a better term. But that option is to simply avoid the stock altogether in favor of deep value names offering some yield protection and are still managing to grow. We would not short down here at $7-$8, as the stock really has been pounded. The risk-reward is not favorable on a short after all of the action. So, you could do nothing and just watch it. If you own the stock, that would be a simple hold then. You could consider selling some upside calls on big bounces to lower cost basis if you choose.The second course of action is in our wheelhouse. And that is to trade the name. Right now, we think that $7 level is a buy for gains to be sold at $8-$9, maybe $10. But this market environment is not going to get any better for innovative tech in the near-term. You could then consider some put options or mild shorts if the stock does enjoy a sizable bounce from the oversold conditions.The third option is likely where a lot of readers are interested, and that is simply invest in the name, not obsess over the day-to-day tick in price. Add selectively to a well-rounded portfolio to improve cost basis, and put faith in management that it can deliver on growing the business profitably without diluting shareholders into oblivion. Right now this is a tall order for this company and management. While operationally the company is growing sufficiently, management has some credibility issues. What one has to do is determine if what the company offers will solve enough headaches for customers that eventually the growing sales turn into sustained and growing profits.For years, Palantir may lose money or breakeven. Of course, the theory goes that companies like this will lose money as they spend to attract customers and build their moat. They invest heavily in their growth while seeing revenues increase dramatically. And as we know, Palantir is seeing revenues grow tremendously.So, what is our take? We think you wait for the next down day in the stock. It has enjoyed a sizable relief bounce from the lows, but we believe the stock will retest these lows as the economy continues to worsen, rates are going up, and markets struggle. We would be both traders and investors at $7. The risk could be that Palantir's growth fades and the company never really transforms the world. New competitors could emerge. Dilution could continue so long that positive EPS becomes out of reach without future buybacks. We hate to say it but frankly, it is not uncommon for stocks in seemingly innovative companies to wither away to sub $1 then eventually delist because the company failed to grow and deliver on its plans.Although we were wrong in that bottom call, operationally we are seeing some positive signs. Internal metrics improve year-after-year for Palantir and we see no reason why the ongoing growth will not eventually lead to real profits, other than dilution. We admit and accept that so many great companies start out losing money. While the Russia/Ukraine conflict was a seemingly bullish development as it highlights a need to mine data for intelligence, some see a limited benefit for Palantir. For the long-term investor, we like a buy in this stock on weakness that sends the stock lower. While it will still be expensive, even for high growth tech, it will be much more reasonable compared to a few months ago. And it is not like the company is bleeding out and losing money hand over first. Palantir is breaking even and making some money some quarters.Palantir's Government and Commercial sectors showing growthIn the just reported quarter, performance was strong on the top line and ahead of consensus estimates. Total revenue grew 31% year-over-year to $446 million, beating estimates by almost $3 million. However, its profitability was lower than expected by $0.02, and worse, guidance was less than consensus. That crushed the stock. But that said, both segments are doing well.Palantir has two reporting segments: both the government and commercial segments. The commercial revenue stream continues to grow rapidly, while government results are likely to get a big boost following international strife. While the war in Ukraine may or may not lead to more business the company has invested in itself to grow sales. There are some concerns with backlog, but as we previously covered, Palantir has been hiring.Palantir has expanded its sales team and they have been working to secure new orders. However, the Government revenues have slowed their growth somewhat. Deceleration of revenue growth is definitely a negative for a company like this that does not enjoy high earnings. They rose 16% from last year, and the company added a total of 40 net new customers in the quarter, which is very positive, 3 on the government side and 37 on the commercial side. We think it is important to note that the commercial space is doing well. The commercial revenue is expanding rapidly, increasing 132% in 2021, and here in Q1, it rose 54% year-over-year.Palantir is seeing very positive momentum in its margins as well. Positive movement in margins is important in a software company as it really highlights strengths, or weaknesses, in the way it distributes its products. Palantir is delivering. Adjusted gross margin was 81%. Contribution margin was 57%. First quarter adjusted income from operations, excluding stock-based compensation and related employer payroll taxes was $117 million, representing an adjusted operating margin of 26%, ahead of management's prior guidance of 23%. This is positive.Palantir is slightly profitable, for nowDespite the pull back now to single-digits, the stock is actually still expensive, like so many other growth tech names. The company lost $39 million in the quarter operationally, but adjusted income from operations was $117 million. The company is still free cash flow positive. Adjusted free cash flow was $30 million for the quarter. That said, the company was profitable at a $0.02 adjusted EPS bottom line figure, but this missed estimated by $0.02, so that is a negative, and another reason the stock is down.We say the company is profitable for now for two reasons. First, there is a ton of stock based-compensation. This has been discussed in the past but we have to reiterate that we like that management has acknowledged that it is a problem. Still, it is ongoing, and every share that is issued waters down the ability to increase EPS. In short, shareholders could be diluted into losses. The second reason is that although there is growth internationally, as well as big gains in the U.S., we could see the government and companies slash spending if there is a recession. Each week, things seem to get worse in terms of how expensive things are, and corporate earnings reports continue to highlight the tremendous pressure inflation is putting on them. While Palantir's technology should help governments and businesses alike operate more efficiently, and therefore more profitably, we could see reduced spending on services like this.Still expensiveOn the valuation front, the stock is still pricey. Sure, looking at traditional price-to-earnings is futile, but if you did you would see a stock at like 50X. Very pricey. Perhaps the more appropriate measure is the price-to-sales ratio, but not only is this still very high, the market has basically said it is no longer willing to pay for sky high multiples. Keep that in mind. At 9X sales, the stock is much cheaper than it has ever been, but it is still not \"cheap\". We would highlight that the PEG ratio is reasonable and we like the cash flow metrics.The outlook is murkyThe biggest concern right now is not valuation. It is not dilution. It is not the \"overall market.\" The largest issue is a slowdown in performance. The Q2 guidance was pretty weak. The company perhaps is underpromising to overdeliver, by management guided to a base case of $470 million in revenue. This was below consensus of $484 million. However in the release management noted that \"there is a wide range of potential upside to [the] guidance.\" The one positive factor to highlight is that Palantir continues to see 30% annual revenue growth through 2025.Take homeThe company operates with no debt and has nice positive free cash flow. They are poised to benefit from strong secular trends in big data and using analytics to improve operations. In the short-term, it is painful. Long-term, minus the dilution issues, there is a lot of promise here for future profits. The customer growth is impressive as is the revenue growth. While the stock has been a disaster, man analysts have price targets implying massive upside. We continue to see ongoing rapid growth in the U.S., but do caution that a big economic slowdown could hurt government and commercial spending. All things considered, on the next drawdown we would be buyers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":107376793,"gmtCreate":1620448288812,"gmtModify":1704343910017,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/107376793","repostId":"104049170","repostType":1,"repost":{"id":104049170,"gmtCreate":1620347039090,"gmtModify":1718129702778,"author":{"id":"3478560277044805","authorId":"3478560277044805","name":"港股解码","avatar":"https://static.tigerbbs.com/0ddf8b49991624b6c7a49b9c67324a01","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3478560277044805","authorIdStr":"3478560277044805"},"themes":[],"title":"中手遊：2021年毛利率有望提升，海外市場將成重要收益來源","htmlText":"得益於公司IP遊戲生態持續深化，以及宅經濟的興起，國內領先的IP遊戲營運商中手遊(00302.HK)2020年經營業績再上一臺階。年內，公司實現營收38.2億元(人民幣，下同)，同比增長25.8%，經調整歸母淨利爲7億元，同比增長183%。其中，代理髮行業務收入達29.8億元，同比增長16.6%，自研遊戲收入達7.3億元，同比增長73.4%，授權業務收入達1.1億元，同比增長81.3%。在靚麗的成績單下，中手遊獲得多家投行的一致看好。2020年以來，累計有超過10家投行給予中手遊增持或買進評級。其中，法國巴黎銀行近日發佈研報指，隨着重點遊戲2021年上線，預計中手遊2021年度收入將達到50.09億元，對應增速爲31.1%。 經調整後淨利潤爲10.21億，對應增速26.5%。基於此，法國巴黎銀行調整中手遊每股目標價爲4.55港元，並給予公司“買入”評級。全方位運營驅動用戶規模破億中手遊是國內少有能進行以受歡迎IP爲基礎的手遊生態系統營運企業，在IP儲備、遊戲開發、遊戲發行及IP授權方面均處於行業領先水平。公司是國內獲得全球最多IP授權開發遊戲產品的企業，同時也是IP遊戲上線數量最多的遊戲公司。在秉持“IP化、精品化、研運一體化、生態化、全球化和品牌化”的六大發展戰略下，中手遊全力打造極具競爭力的IP遊戲生態體系，極大驅動了中手遊2020年運營數據的高速增長。運營數據方面，中手遊用戶數量在2020年穩健提升。年內，公司遊戲新註冊用戶總數破億，達到1.02億人，同比增長18.6%；平均每月活躍用戶1848.3萬人，同比增長16%；月付費用戶達141.4萬人，平均付費率爲7.7%，同比增長0.2個百分點。在豐富的遊戲組合及強大的遊戲儲備推動下，中手遊2020年線上活躍遊戲達到81款，其中15款遊戲生命週期超過3年，而其他手遊開發及發行商的平均活躍遊戲爲25款。其中，中手遊在4月2","listText":"得益於公司IP遊戲生態持續深化，以及宅經濟的興起，國內領先的IP遊戲營運商中手遊(00302.HK)2020年經營業績再上一臺階。年內，公司實現營收38.2億元(人民幣，下同)，同比增長25.8%，經調整歸母淨利爲7億元，同比增長183%。其中，代理髮行業務收入達29.8億元，同比增長16.6%，自研遊戲收入達7.3億元，同比增長73.4%，授權業務收入達1.1億元，同比增長81.3%。在靚麗的成績單下，中手遊獲得多家投行的一致看好。2020年以來，累計有超過10家投行給予中手遊增持或買進評級。其中，法國巴黎銀行近日發佈研報指，隨着重點遊戲2021年上線，預計中手遊2021年度收入將達到50.09億元，對應增速爲31.1%。 經調整後淨利潤爲10.21億，對應增速26.5%。基於此，法國巴黎銀行調整中手遊每股目標價爲4.55港元，並給予公司“買入”評級。全方位運營驅動用戶規模破億中手遊是國內少有能進行以受歡迎IP爲基礎的手遊生態系統營運企業，在IP儲備、遊戲開發、遊戲發行及IP授權方面均處於行業領先水平。公司是國內獲得全球最多IP授權開發遊戲產品的企業，同時也是IP遊戲上線數量最多的遊戲公司。在秉持“IP化、精品化、研運一體化、生態化、全球化和品牌化”的六大發展戰略下，中手遊全力打造極具競爭力的IP遊戲生態體系，極大驅動了中手遊2020年運營數據的高速增長。運營數據方面，中手遊用戶數量在2020年穩健提升。年內，公司遊戲新註冊用戶總數破億，達到1.02億人，同比增長18.6%；平均每月活躍用戶1848.3萬人，同比增長16%；月付費用戶達141.4萬人，平均付費率爲7.7%，同比增長0.2個百分點。在豐富的遊戲組合及強大的遊戲儲備推動下，中手遊2020年線上活躍遊戲達到81款，其中15款遊戲生命週期超過3年，而其他手遊開發及發行商的平均活躍遊戲爲25款。其中，中手遊在4月2","text":"得益於公司IP遊戲生態持續深化，以及宅經濟的興起，國內領先的IP遊戲營運商中手遊(00302.HK)2020年經營業績再上一臺階。年內，公司實現營收38.2億元(人民幣，下同)，同比增長25.8%，經調整歸母淨利爲7億元，同比增長183%。其中，代理髮行業務收入達29.8億元，同比增長16.6%，自研遊戲收入達7.3億元，同比增長73.4%，授權業務收入達1.1億元，同比增長81.3%。在靚麗的成績單下，中手遊獲得多家投行的一致看好。2020年以來，累計有超過10家投行給予中手遊增持或買進評級。其中，法國巴黎銀行近日發佈研報指，隨着重點遊戲2021年上線，預計中手遊2021年度收入將達到50.09億元，對應增速爲31.1%。 經調整後淨利潤爲10.21億，對應增速26.5%。基於此，法國巴黎銀行調整中手遊每股目標價爲4.55港元，並給予公司“買入”評級。全方位運營驅動用戶規模破億中手遊是國內少有能進行以受歡迎IP爲基礎的手遊生態系統營運企業，在IP儲備、遊戲開發、遊戲發行及IP授權方面均處於行業領先水平。公司是國內獲得全球最多IP授權開發遊戲產品的企業，同時也是IP遊戲上線數量最多的遊戲公司。在秉持“IP化、精品化、研運一體化、生態化、全球化和品牌化”的六大發展戰略下，中手遊全力打造極具競爭力的IP遊戲生態體系，極大驅動了中手遊2020年運營數據的高速增長。運營數據方面，中手遊用戶數量在2020年穩健提升。年內，公司遊戲新註冊用戶總數破億，達到1.02億人，同比增長18.6%；平均每月活躍用戶1848.3萬人，同比增長16%；月付費用戶達141.4萬人，平均付費率爲7.7%，同比增長0.2個百分點。在豐富的遊戲組合及強大的遊戲儲備推動下，中手遊2020年線上活躍遊戲達到81款，其中15款遊戲生命週期超過3年，而其他手遊開發及發行商的平均活躍遊戲爲25款。其中，中手遊在4月2","images":[{"img":"https://static.tigerbbs.com/9277094e7e5e6cc04af213f5b3efd57a","width":"576","height":"476"},{"img":"https://static.tigerbbs.com/c3035a74b86f2bc8ec271da25db844ca","width":"594","height":"393"},{"img":"https://static.tigerbbs.com/158ac7f1111af02289bd5b875ca90232","width":"600","height":"368"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/104049170","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":32,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803293762,"gmtCreate":1627439678656,"gmtModify":1703489992445,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Anyone drinking beers","listText":"Anyone drinking beers","text":"Anyone drinking beers","images":[{"img":"https://static.tigerbbs.com/2bfc4834d8c3e481cb02a247326c4a8f","width":"1125","height":"2793"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803293762","isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":178477161,"gmtCreate":1626834797553,"gmtModify":1703766101583,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178477161","repostId":"2153761308","repostType":2,"isVote":1,"tweetType":1,"viewCount":653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":315223422099496,"gmtCreate":1717990269853,"gmtModify":1717990271913,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/315223422099496","repostId":"2441307342","repostType":2,"repost":{"id":"2441307342","pubTimestamp":1717988788,"share":"https://ttm.financial/m/news/2441307342?lang=&edition=fundamental","pubTime":"2024-06-10 11:06","market":"us","language":"en","title":"3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)","url":"https://stock-news.laohu8.com/highlight/detail?id=2441307342","media":"Motley Fool","summary":"Palantir's latest AI product has been a game changer for the company.","content":"<html><head></head><body><ul style=\"\"><li><p>Palantir&#39;s revenue growth accelerated, thanks to AIP.</p></li><li><p>Management steadily guided for its profit margins to increase.</p></li><li><p>However, the stock is expensive for its growth rate.</p></li></ul><p>In the realm of artificial intelligence (AI) software, Palantir Technologies sticks out from the rest. Palantir has been in the AI business since its founding in 2003. Originally created to assist governments in processing data to deliver actionable insights, it has since expanded into the public sector, opening up a new business avenue.</p><p>With Palantir&#39;s multiple decades of expertise, it&#39;s becoming a top pick for companies looking to integrate AI models and decision-making into their businesses. Investors are noticing that momentum, piling into the stock as a result.</p><p>I agree that Palantir is a top AI pick, and I have three reasons why it&#39;s a buy. But I have one reason to avoid the stock, and it may trump the rest.</p><h2 id=\"id_1590136905\">Reason to buy 1: Palantir&#39;s latest product has been a hit</h2><p>While some of Palantir&#39;s AI tools have been around for a while, its latest product, Artificial Intelligence Platform (AIP), has been all the rage. While AIP probably could have used a better name (Palantir&#39;s other products sport cooler names like Foundry, Gotham, and Apollo), it gets the point across for what it does.</p><p>AIP gives clients the tools they need to integrate AI into everyday workflows. By centralizing all data flows into one location, AIP helps businesses make decisions on the most up-to-date information they have. It also allows large language model integration (the technology behind generative AI), which further arms users to automate and streamline workflows.</p><p>Palantir&#39;s management consistently used the word &#34;unprecedented&#34; when discussing AIP demand, and this platform will be a major revenue driver for years to come.</p><h2 id=\"id_3457250373\">Reason to buy 2: Revenue growth is accelerating</h2><p>Due to the &#34;unprecedented&#34; demand, Palantir&#39;s revenue growth has been accelerating. In Q1, revenue grew at a 21% clip to $634 million, the fastest pace since late 2022.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/398901b69af0a0d6cedf1e6549522e0d\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR Revenue (Quarterly YoY Growth) data by YCharts</p><p>But Palantir isn&#39;t stopping there. In Q2, management expects revenue of $651 million, indicating 22% revenue growth. Growth acceleration is something investors love to see, and its quicker growth rates help justify the stock price.</p><p>Still, Palantir isn&#39;t just a growth-at-all-costs company.</p><h2 id=\"id_1319693756\">Reason to buy 3: Palantir&#39;s margins continue to improve</h2><p>Palantir flipped the profitability switch in 2023 when it started producing small profits. Since then, its profit margins have continued to steadily tick up, which can be an incredibly powerful combination when revenue growth is also accelerating.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0a76b561140032c2fb8f417ebc677628\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR Profit Margin (Quarterly) data by YCharts</p><p>Palantir&#39;s management understands that investors want to see profits eventually, so it is aligning business results with shareholder expectations. </p><h2 id=\"id_4137751275\">Reason to avoid: Palantir&#39;s stock is far from cheap</h2><p>Palantir checks all the boxes from a business outlook and financial standpoint, but there&#39;s still one more factor to consider: its price tag.</p><p>Even if everything about a stock is perfect, buying it at the wrong price can be a disaster. For example, <strong><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications</strong> was a no-brainer stock during the pandemic. It had unbelievable growth, strong profits, and an incredible outlook, but anyone who bought at elevated levels in late 2020 is down nearly 90% from their initial investment.</p><p>Palantir&#39;s stock hasn&#39;t reached near the hubris as Zoom Video&#39;s did, but it&#39;s still valued at a hefty premium.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3cb97bd6ab11a774071bcb94f5fa4077\" tg-width=\"720\" tg-height=\"441\"/></p><p>PLTR PS Ratio data by YCharts</p><p>At 21 times sales, its price-to-sales (P/S) ratio is nearly equal to its growth rate. This normally doesn&#39;t bode well for a stock, as it indicates incredibly high growth expectations.</p><p>But is that enough to completely avoid the stock? I don&#39;t think so. If investors avoided companies like <strong>Amazon </strong>or <strong>Nvidia </strong>because they were too expensive, they&#39;d have missed out on massive winners. However, highly priced stocks can be volatile, so you&#39;ll need to set a longer holding period of around five years to make it worth it.</p><p>If you can do that, then Palantir could be a fantastic AI investment at these levels.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons to Buy Palantir Stock (and 1 Reason to Avoid It)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-10 11:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir's revenue growth accelerated, thanks to AIP.Management steadily guided for its profit margins to increase.However, the stock is expensive for its growth rate.In the realm of artificial ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc.","BK4548":"巴美列捷福持仓","BK4543":"AI","BK4547":"WSB热门概念","BK4551":"寇图资本持仓","BK4097":"系统软件","BK4505":"高瓴资本持仓","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4528":"SaaS概念","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4023":"应用软件","BK4525":"远程办公概念","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4535":"淡马锡持仓"},"source_url":"https://www.fool.com/investing/2024/06/08/3-reasons-to-buy-palantir-stock-and-1-reason-to-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2441307342","content_text":"Palantir's revenue growth accelerated, thanks to AIP.Management steadily guided for its profit margins to increase.However, the stock is expensive for its growth rate.In the realm of artificial intelligence (AI) software, Palantir Technologies sticks out from the rest. Palantir has been in the AI business since its founding in 2003. Originally created to assist governments in processing data to deliver actionable insights, it has since expanded into the public sector, opening up a new business avenue.With Palantir's multiple decades of expertise, it's becoming a top pick for companies looking to integrate AI models and decision-making into their businesses. Investors are noticing that momentum, piling into the stock as a result.I agree that Palantir is a top AI pick, and I have three reasons why it's a buy. But I have one reason to avoid the stock, and it may trump the rest.Reason to buy 1: Palantir's latest product has been a hitWhile some of Palantir's AI tools have been around for a while, its latest product, Artificial Intelligence Platform (AIP), has been all the rage. While AIP probably could have used a better name (Palantir's other products sport cooler names like Foundry, Gotham, and Apollo), it gets the point across for what it does.AIP gives clients the tools they need to integrate AI into everyday workflows. By centralizing all data flows into one location, AIP helps businesses make decisions on the most up-to-date information they have. It also allows large language model integration (the technology behind generative AI), which further arms users to automate and streamline workflows.Palantir's management consistently used the word \"unprecedented\" when discussing AIP demand, and this platform will be a major revenue driver for years to come.Reason to buy 2: Revenue growth is acceleratingDue to the \"unprecedented\" demand, Palantir's revenue growth has been accelerating. In Q1, revenue grew at a 21% clip to $634 million, the fastest pace since late 2022.PLTR Revenue (Quarterly YoY Growth) data by YChartsBut Palantir isn't stopping there. In Q2, management expects revenue of $651 million, indicating 22% revenue growth. Growth acceleration is something investors love to see, and its quicker growth rates help justify the stock price.Still, Palantir isn't just a growth-at-all-costs company.Reason to buy 3: Palantir's margins continue to improvePalantir flipped the profitability switch in 2023 when it started producing small profits. Since then, its profit margins have continued to steadily tick up, which can be an incredibly powerful combination when revenue growth is also accelerating.PLTR Profit Margin (Quarterly) data by YChartsPalantir's management understands that investors want to see profits eventually, so it is aligning business results with shareholder expectations. Reason to avoid: Palantir's stock is far from cheapPalantir checks all the boxes from a business outlook and financial standpoint, but there's still one more factor to consider: its price tag.Even if everything about a stock is perfect, buying it at the wrong price can be a disaster. For example, Zoom Video Communications was a no-brainer stock during the pandemic. It had unbelievable growth, strong profits, and an incredible outlook, but anyone who bought at elevated levels in late 2020 is down nearly 90% from their initial investment.Palantir's stock hasn't reached near the hubris as Zoom Video's did, but it's still valued at a hefty premium.PLTR PS Ratio data by YChartsAt 21 times sales, its price-to-sales (P/S) ratio is nearly equal to its growth rate. This normally doesn't bode well for a stock, as it indicates incredibly high growth expectations.But is that enough to completely avoid the stock? I don't think so. If investors avoided companies like Amazon or Nvidia because they were too expensive, they'd have missed out on massive winners. However, highly priced stocks can be volatile, so you'll need to set a longer holding period of around five years to make it worth it.If you can do that, then Palantir could be a fantastic AI investment at these levels.","news_type":1},"isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807706941,"gmtCreate":1628054725583,"gmtModify":1703500377391,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Turn to RED MOON now!","listText":"Turn to RED MOON now!","text":"Turn to RED MOON now!","images":[{"img":"https://static.tigerbbs.com/2ef0259d7e3fb071dde7bf5e6836d5ba","width":"1125","height":"2083"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807706941","isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":809384115,"gmtCreate":1627348416737,"gmtModify":1703488044503,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Nice beer, Samual Adam","listText":"Nice beer, Samual Adam","text":"Nice beer, Samual Adam","images":[{"img":"https://static.tigerbbs.com/8c81143c8d7d05e9c1d1bf9c10749ede","width":"1125","height":"2629"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/809384115","isVote":1,"tweetType":1,"viewCount":317,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":171610471,"gmtCreate":1626741415893,"gmtModify":1703764176642,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Chewy! Chewy!","listText":"Chewy! Chewy!","text":"Chewy! Chewy!","images":[{"img":"https://static.tigerbbs.com/f02a25ede97c39da8a92b841931a4183","width":"1125","height":"2425"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/171610471","isVote":1,"tweetType":1,"viewCount":71,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143853115,"gmtCreate":1625788900337,"gmtModify":1703748465046,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Worth researching Abbots&nbsp;","listText":"Worth researching Abbots&nbsp;","text":"Worth researching Abbots","images":[{"img":"https://static.tigerbbs.com/b9816c04b35845a61d22ae23b98fae62","width":"1125","height":"2069"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143853115","isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143090484,"gmtCreate":1625751710148,"gmtModify":1703747806328,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"When is the right timing to enter?","listText":"When is the right timing to enter?","text":"When is the right timing to enter?","images":[{"img":"https://static.tigerbbs.com/294a6040baa314b1cd484be55f7866f2","width":"1125","height":"2412"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143090484","isVote":1,"tweetType":1,"viewCount":121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":143004853,"gmtCreate":1625751654172,"gmtModify":1703747802596,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"Almost become a cinema giants&nbsp;","listText":"Almost become a cinema giants&nbsp;","text":"Almost become a cinema giants","images":[{"img":"https://static.tigerbbs.com/928369ace60bca0c682b3944162903fd","width":"1125","height":"2330"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143004853","isVote":1,"tweetType":1,"viewCount":78,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":153853768,"gmtCreate":1625018518454,"gmtModify":1703850222383,"author":{"id":"3574328305423311","authorId":"3574328305423311","name":"Simm","avatar":"https://static.tigerbbs.com/1ef382cd57b5304b69b03a52cb252316","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574328305423311","authorIdStr":"3574328305423311"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02150\">$NAYUKI(02150)$</a>?","listText":"<a href=\"https://laohu8.com/S/02150\">$NAYUKI(02150)$</a>?","text":"$NAYUKI(02150)$?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153853768","isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}